

Curriculum Vitae

Hartmut Horst Malluche, M.D., F.A.C.P.

Professor and Chief

Robert G. "Robin" Luke Chair in Nephrology

I. GENERAL INFORMATION

Office Address: Division of Nephrology, Bone and Mineral Metabolism
Department of Internal Medicine
University of Kentucky Medical Center
800 Rose Street, Room MN 564
Lexington, Kentucky 40536-0298
Phone: (859) 323-5049; Fax: (859) 323-0232

II. EDUCATION

1957-63 Albertus Magnus College
Koenigstein/Taunus, Germany
Degree: Abitur

1963-65 Medical School, Phillips University
Marburg/L., West Germany

1966-67 Medical School, University of Innsbruck and University of Vienna, Austria

1967-69 Medical School, J.W. Goethe University
Frankfurt am Main, West Germany

1969 Final medical exam (Summa cum laude), J.W. Goethe University
Frankfurt am Main, West Germany

1971 Doctoral Degree of Medicine, J.W. Goethe University
Frankfurt am Main, West Germany

1974 Accredited Board of Internal Medicine, Germany

1975 Accredited Subspecialty Board of Nephrology, Germany

III. PROFESSIONAL EXPERIENCE

March 1969-March 1970 County Hospital (Internship)
Aichach, West Germany

April 1970-July 1975 Center of Internal Medicine (Residency and Fellowship)
University Hospitals, J.W. Goethe University
Frankfurt am Main, West Germany

August 1975-July 1978 Los Angeles County/Univ. of Southern California
Medical Center (Assistant Professor of Medicine)
Department of Internal Medicine, Division of Nephrology
Los Angeles, California

August 1978-September 1981 Los Angeles County/Univ. of Southern California
Medical Center (Associate Professor of Medicine)
Department of Internal Medicine, Division of Nephrology
Los Angeles, California

- January 2000 – October 2005 Program Director, General Clinical Research Center
University of Kentucky
- October 1981–present Professor of Medicine and Chief
Division of Nephrology, Bone and Mineral Metabolism
Department of Internal Medicine
University of Kentucky
Lexington, Kentucky
- January 1985–present Active Scientific Staff
Shriner’s Hospital for Crippled Children, Lexington Unit
Lexington, Kentucky

IV. ACADEMIC/HOSPITAL APPOINTMENTS

- 1975 Habilitation (Privat Dozent)
J.W. Goethe University
Frankfurt am Main, West Germany
- 1977 Visiting Assistant Professor of Medicine
University of Southern California
Los Angeles, California
- 1978 Tenured Associate Professor of Medicine
University of Southern California
Los Angeles, California
- 1981 Professor of Internal Medicine
University of Kentucky
Lexington, Kentucky
- 1988 Professor of Internal Medicine & Toxicology
University of Kentucky
Lexington, Kentucky
- 2000 Appointed by University of Kentucky Board of Trustees to
Robert G. “Robin” Luke Chair in Nephrology

V. CONSULTATIVE SERVICES

- VA Merit Reviewer: 1982, 1985, 1986, 1992
NIH Consultant, Special Study Section: 1983
Grant Reviewer, Kidney Foundation of Canada: 1984, 1986
Reviewer for American Society of Nephrology for Annual Meeting, Washington, DC.
Topics: Calcium, Phosphorus, PTH, Vitamin D: 1983
Grant Reviewer, New York University: 1984
NIH Consultant, Site Visit: 1984
Reviewer of Doctoral Thesis of the Univ. of Johannesburg, S. Africa: 1984
NIH Consultant, Special Study Section: 1985
Reviewer, Study Section, National Institute of Mental Health: 1985
NIH Outside Reviewer, General Medicine B Study Section: 1985
NIH Special Reviewer for Orthopedic Study Section: 1985
Grant Reviewer, National Science Foundation: 1985
Consultant, Food and Drug Administration: 1986
NIH Special Reviewer for Special Study Section: 1986
VA Reviewer for Career Development Award: 1986
Member, Study Section of National Institute of Mental Health: 1986
NIH Consultant, Site Visit, Washington University, 1987

Member, Merit Review Board for Nephrology, Veterans Administration, 1988–91
Member NCI Site Visit Team, “Cooperative Core Lab and Clinical Nutrition Research,” Memorial Hospital for Cancer and Allied Disease, (Memorial Sloan–Kettering Cancer Center, Cornell University, Rockefeller University, North Shore University, Hospital for Special Surgery) New York, NY 1990
Reviewer: National Osteoporosis Foundation, 1989–1994
Reviewer for American Society of Nephrology for Annual Meeting, Washington, DC., 1990 Topics: Calcium, Magnesium, Phosphorus; Parathyroid Hormone/Vitamin D; Mineral Metabolism
Member NIH Orthopedics and Musculoskeletal Study Section, February, 1992
Grant Reviewer, Food and Drug Administration, 1992
American Heart Association Kidney Council, 1993–1994
NIH Consultant, NIEHS Lead Bone Metabolism Workshop, Raleigh–Durham, NC, 1993
NIH Consultant, Conference on Morbidity and Mortality in Dialysis Patients, Bethesda, MD, 1993
Member, FDA Metabolism Review Panel, Rockville, MD, 1994
NIH Expert Consultant, Nephrology, Bone and Mineral Metabolism, 1994
FDA Arthritis Advisory Committee, Invited Consultant, Washington, DC, 1996
VA Merit Reviewer, 1997
Consultant, National Metabolic Bone Disease Consultants Meeting, January, 1998
Consultant, National Metabolic Bone Disease Consultants Meeting, January, 1999
Consultant, National Metabolic Bone Disease Consultants Meeting, February, 2000
Advisor, FDA Division of Cardio-Renal Drug Products Meeting, April 2000
NIH Scientific Reviewer – RIRG-G 01 Workgroup 008, Albert Einstein University, 2001
Reviewer, German-Israeli Foundation for Scientific Research & Development, 2002
Member, Clinical Research Study Section, National Institutes of Health, 2002-present
American Editor: Clinical Nephrology for North America and Canada, 1998-2002
Editor-in-Chief: Clinical Nephrology for North and South America and Canada, 2002-present
Member, Clinical Research Review Committee, National Institutes of Health, 2003-present
Chairman, National Center for Research Resources, Clinical Research Review Committee, September, 2003
Member, Special Emphasis Panel, National Institute of Arthritis & Musculoskeletal & Skin Diseases, October, 2003
Member, National Institutes of Health/National Center for Research Resources-GCRC Study Section, February 2004
Member, National Center for Research Resources/GCRC Site Visit, Rockefeller University, May 2004
Invited Reviewer: MD/PhD Thesis, Aranxta Rodriguez, University of Oviedo, Oviedo, Spain, May 2004
Member, National Institutes of Health/National Center for Research Resources-GCRC Study Section, June 2004
Member, National Center for Research Resources/GCRC University of Oklahoma Site Visit, July 2004
Member, National Center for Research Resources Special Emphasis Panel, Bethesda, MD, November 2004
Member, National Center for Research Resources/GCRC University of California, San Diego Site Visit, December 2004
Member, National Institutes of Health/National Center for Research Resources-GCRC Study Section, February 2005
Chairman, National Institutes of Health/National Center for Research Resources/GCRC Site Visit, Wake Forest University, Winston-Salem, NC, April 2005
Member, National Institutes of Health Special Emphasis Panel Telephone Study Section, May 2005
Member, National Center for Research Resources-GCRC Study Section, June 2005
Member, National Center for Research Resources/GCRC University of Vermont, Burlington, VT, August 2005
Member, National Institutes of Health Special Emphasis Panel, Bethesda, MD, October 2005
Member, National Center for Research Resources, Clinical Research Review Committee, October 2005
Member, National Institute of Arthritis and Musculoskeletal and Skin Disease, Special Emphasis Panel, December 2005
Member, NIH Center for Research Resources/GCRC Site Visit, University of Tennessee, December 2005
Member, NIH Center for Research Resources, Clinical Research Review Committee, February 2006
Member, NIH Center for Research Resources Special Emphasis Panel; Loan Repayment Program SEP, May 2006
Member, NIH Center for Research Resources, Clinical Research Review Committee, June 2006
NIH Special Reviewer for Loan Repayment Program, April 2007
Member, NIH Special Emphasis Panel, Center for Research Resources, July 2007

NIH Center for Scientific Review, 2007
 Renal & Urological Sciences IRG, 2007
 Kidney Monitoring and Therapeutics Small Business Review, 2007
 NIH Special Reviewer for Loan Repayment Program, April 2008
 Member, NIH Special Emphasis Panel, Center for Research Resources, April 2008
 Reviewer for Scientific Program of American Society of Nephrology Annual Meeting, Philadelphia, PA.,
 November 2008
 Active Preceptor: University of Kentucky, College of Public Health, 2008
 NIH, Center for Scientific Review Special Emphasis Panel, February 2009

Administrative Activity/Committees

Chairman, Scientific Adv. Council of National Kidney Foundation Kentucky East, 1983 – 1985
 Member, Promotions Committee, Department of Medicine, University Kentucky, 1982 – 86
 Chairman, Promotions Committee, Department of Medicine, University of Kentucky, 1987 – 89
 Member, Chairman's Advisory Council, Department of Medicine, University of Kentucky, 1985 – present
 Member Scientific Advisory Council, National Kidney Foundation, Kentucky, 1990 – present
 Member, Chairman's Advisory Committee, Department of Internal Medicine, University of Kentucky,
 1991 – present
 Member, Board of Directors, Advances in Mineral Metabolism Annual Conferences, 1992 – present
 Organizer, Shriners Scientists Meeting, Washington, DC, 1992
 President, International Congress on Bone Morphometry, Lexington KY, 1992
 College of Medicine Research Committee, 1992 –1995
 Member, Executive Committee, Department of Internal Medicine, University of Kentucky
 1993 – present
 Member, Academic Affairs Advisory Committee, University of Kentucky, 1993 – present
 Secretary, Medical Director's Advisory Committee, Dialysis Clinic, Inc. 1994 – 1995
 Chairman, Medical Director's Advisory Committee, Dialysis Clinic, Inc. 1995 – 1996
 Founder, International Society of Bone Morphometry, 1995
 Vice President, International Society of Bone Morphometry, 1995 – 1996
 Secretary/Treasurer, International Society of Bone Morphometry, 1997 – 2005
 University of Kentucky Institutional Representative for the American Society of Clinical Investigation,
 1997 – present
 Member, Educational Review Committee for Department of Preventive Medicine and Environmental Health,
 1999
 Chairman, Clinical Research Committee, Department of Internal Medicine, University of Kentucky, 1999–2001
 Dialysis Outcome Quality Improvement Bone & Mineral Metabolism Work Group, 2000
 Member, Committee on Faculty Appointments, Appeals, Promotions and Tenure, 2000 – 2003
 Ex-Officio Member, General Clinical Research Committee, 2000 - 2005
 Member, National Kidney Foundation KDOQI Guidelines on Bone Disease, 1999 - 2000
 Member, Advisory Committee, University of Kentucky Clinical Research Organization, 2002 - 2005
 Associate Member of the Graduate Faculty of the University of Kentucky, 2005 – present
 Member, Kidney Disease – Improving Global Outcome (KDIGO) – National Kidney Foundation International
 Committee, 2005
 Member, Board of Directors, International Society of Bone Morphometry, 2005 - 2008

Selected Honors

Who's Who in Frontiers of Science and Technology, 1985
 Who's Who in the World, listed annually since 1987
 Who's Who in Science & Engineering, 2nd edition, 1993
 Who's Who Life Member, 2001
 Distinguished Lecturer Award: Chinese Society of Nephrology, Taiwan, 1992
 100 Best Doctors in America, 1996 – 2004
 100 Best Doctors in America, 2007 – 2008

Honorary Member, Australian and New Zealand Society of Nephrology, 1996 – Present
 National Leadership Award, Honorary Chairman, Physicians' Advisory Board, 2003
 Honorable Order of Kentucky Colonels, 2003
 Business Advisory Council, Businessman of the Year, 2003
 Appreciation for Valuable Contributions, Swedish Society of Medicine, 2003
 Honorary Member, Australian & New Zealand Society of Nephrology, 2005 - Present
 Honorary Member, South African Renal Association (Honorary Member), 2006 - Present
 Clinical and Translational Science Mentor Recognition Award, University of Kentucky, 2006

Speaking Engagements

Invited Participant in Panel: “Can Renal Bone Disease be Prevented?”
 European Dialysis and Transplant Assoc. Annual Meeting, Vienna, 1973
 Invited Speaker: “Role of Vitamin D Metabolism in Management of Bone Abnormalities in Renal Disease: State of the Art Address,” IVth International Workshop on Phosphate and Other Minerals, Strassburg, France, 1979
 Visiting Professor: University of Oklahoma, August 1981
 Invited Speaker: “Bone Histomorphometry for the Non-Histomorphometrist,” Annual Meeting of the American Society for Bone and Mineral Research, San Francisco CA, 1982
 Chairman, Session: “Metabolic Bone Disease,” Annual Meeting of the American Society of Nephrology, Chicago IL, 1982
 Visiting Professor: University of Heidelberg, West Germany, 1982
 Visiting Professor: Medical College of Ohio at Toledo, Toledo OH, 1982
 Keynote Speaker: “New Developments in the Diagnosis and Management of Metabolic Bone Disease,” Scientific Program, American College of Physicians, Louisville KY, 1982
 Chairman, Session: “Acute Renal Failure,” Annual Meeting of the American Society of Nephrology, Washington DC, 1983
 Visiting Professor: Ohio State University, Columbus OH, 1983
 Visiting Professor: Duke University, Durham NC, 1983
 Visiting Professor: University of Cincinnati OH, 1983
 Visiting Professor: University of Heidelberg, West Germany, 1983
 Visiting Professor: University of Louvain, Brussels, Belgium, 1983
 Visiting Professor: J.W. Goethe University, Frankfurt am Main, West Germany, 1983
 Visiting Professor: Medical College of Ohio at Toledo, Toledo OH, 1984
 Visiting Professor: University of San Antonio, San Antonio TX, 1984
 Invited Speaker: Howard A. Swart Memorial Lecture, The Tri-State Orthopedic Society, 1984
 Visiting Professor: University of Bern, Switzerland, 1985
 Member: Organizing Committee, 3rd Int. Workshop on Bone Histomorphometry, Sun Valley CA, 1986
 Invited Speaker: SEDTA Annual Meeting, 1986
 Speaker: “Advances in Mineral Metabolism,” Snowmass CO, 1986
 Visiting Professor: University of Louisville, Louisville KY, 1986
 Visiting Professor: University of Heidelberg, West Germany, 1986
 Member: Committee of The American Society of Bone and Mineral Research for Nomenclature in Bone Histomorphometry, 1986
 Speaker: New York Society of Nephrology, Mt. Sinai Medical Center and The Hospital for Special Surgery, New York NY, 1987
 Speaker: Saint Joseph Hospital, Orange CA, 1987
 Invited Speaker: 4th International Symposium on Bone, Structure, Function and Disease, Sydney, Australia, 1987
 Visiting Professor: J.W. Goethe University, 1987
 Invited Speaker: International Congress of Nephrology, 1987
 Member and Invited Speaker: International Organizing Committee, 5th International Congress on Bone Morphometry, Niigata, Japan, 1988
 Visiting Professor: Brown University, Rhode Island, 1988
 Invited Speaker: St. Markus-Krankenhaus, Goethe University, West Germany, 1988
 Invited Speaker: Klinikum der Johannes Gutenberg-Universität, West Germany, 1988
 Invited Speaker: Clinical Disorders of Bone and Mineral Metabolism Int. Symposium, Detroit MI, 1988

Invited Speaker: Advances in Mineral Metabolism, Snowmass CO, 1989
 Invited Speaker: Kidney Foundation, Knoxville, TN 1989
 Invited Speaker: National Kidney Foundation of Northern California 22nd Annual Symposium on Renal Disease, San Francisco CA, 1989
 Invited Speaker: "Clinical Update on Rocaltrol," symposium at 71st Annual Meeting of the Endocrine Society, Seattle WA, 1989
 Visiting Professor: Erfurt, German Democratic Republic, 1989
 Invited Speaker: International Meeting "Calcium 89," Prague, Czechoslovakia, 1989
 Invited Speaker and Chairman: Symposium on Bone Mass, Orthopedic Research Society, New Orleans LA, 1990
 Invited Speaker: 5th Annual Meeting of Deutsche Gesellschaft für Osteologie, 1990
 Invited Speaker: Grand Rounds, Booth Memorial Hospital, New York NY, 1990
 Member Organizing Committee: Renal Bone Disease, Parathyroid Hormone and Vitamin D Symposium in Tokyo, Japan, 1990
 Invited Speaker: Annual Meeting of Nephrology/National Kidney Foundation, December 1990
 Invited Speaker: Symposium—Innovative Aspekte der Nephrologie, Heidelberg, 1990
 Invited Speaker: Purdue University, 1990
 Invited Speaker: University of Cincinnati, 1990
 Chairman: Annual Meeting American Society of Nephrology, Session "Vitamin D in Renal Failure," 1990
 Invited Speaker: National Kidney Foundation Annual Meeting, 1990
 Invited Speaker: University of Heidelberg, Germany, 1990
 Invited Speaker: International Dialysis Symposium, Ulm, Germany, 1991
 Invited Speaker: German Society of Osteology, Aachen, Germany, 1991
 Invited Speaker: Mini-lecture American Society of Nephrology Annual Meeting, 1991
 Invited Speaker: MMV Pharmaceutical Award Symposium Desferal, ETH Zurich, 1991.
 Invited Speaker: Consensus Conference on the Diagnosis and Treatment of Aluminum Overload in Dialysis Patients, Paris, 1992
 Invited Speaker: National Kidney Foundation of Texas, Dallas TX, 1992
 Invited Speaker: Advances in Mineral Metabolism, Snowmass CO, 1992
 Invited Speaker: International Conference: Frontiers in Renal Disease, Monte Carlo, 1992
 Invited Speaker and Chairperson: Annual Meeting of the German Society of Osteology, Erlangen, Germany, 1992
 Invited Speaker: 3rd Japanese Medical Advisory Board Meeting, Tokyo, Japan, 1992
 Invited Speaker: National Taiwan University Hospital, Taipei, Taiwan, 1992
 Invited Speaker: Institute of Biology and Anatomy, NDMC, Taipei, Taiwan, 1992
 Invited Speaker: Taichung Veterans General Hospital, Taichung, Taiwan, 1992
 Invited Speaker: Kaohsiung Medical Center, Kaohsiung, Taiwan, 1992
 Invited Speaker: Annual convention of The Society of Nephrology, Republic of China, Taipei, Taiwan, 1992
 Invited Speaker: Universität Ulm, Workshop Aktuelle Nephrologie, Ulm, Germany, 1992
 Invited Speaker: Division of Nephrology, Henry Ford Hospital, Detroit MI, 1992
 Invited Speaker: University Berlin, Berlin, Germany, 1992
 Invited Speaker: Harvard Medical School (Seminars in Dialysis), Boston MA, 1993
 Speaker: "Advances in Mineral Metabolism," Snowmass CO, 1993
 Invited Speaker: National Kidney Foundation Annual Meeting, Chicago IL, 1993 (Expert Physician)
 Invited Speaker: American Society for Artificial Internal Organs, New Orleans LA 1993
 Co-Chairman: Session "Clinical Disorders in Mineral Metabolism," XII International Congress of Nephrology, Jerusalem, Israel, 1993
 Visiting Professor: University of Frankfurt, Frankfurt, Germany, 1993
 Invited Speaker: Short Clinical Course at ASN 1993 Annual Meeting, Boston MA
 Invited Discussant: NIA/NIDR Workshop on Human Models of Skeletal Aging, Washington DC, 1994
 Invited Speaker: 9th Annual Meeting German Society of Osteologie, 1994
 Chairman: Fortieth Annual Meeting of the Orthopedic Research Society, Session 10, Bone Structure and Mechanics, New Orleans LA, 1994
 Invited Speaker: Dallas Nephrology Associates Clinical Research Institute, Dallas TX, 1994
 Invited Speaker: University of Texas Southwestern Medical School Nephrology Division, Dallas TX, 1994
 Invited Speaker: Jahrestagung der Deutschen Gesellschaft für Osteologie, Köln, 10. bis 12. März, 1994
 Invited Speaker: Animal Models for Osteoporosis, Snowmass CO, 1994

Invited Speaker: Albert Einstein College of Medicine, Grand Rounds, Bronx NY, 1994
 Invited Speaker: Annual Meeting Tri-State Renal Network 1994 Nephrology Conference, Indianapolis IN, 1994
 Invited Speaker: Dialyze Symposium, Vienna, 1994
 Invited Speaker: 31st Annual Meeting European Dialysis & Transplant Association Annual Meeting, Vienna, 1994
 Invited Speaker and Team Leader: Consensus Conference on Renal Osteodystrophy, Chicago IL, 1994
 Co-Organizer and Speaker of International Meeting: Nephrology on the Verge of the Century, Ulm, Germany, 1994
 Invited Speaker: 2nd International Symposium on Bone and Mineral Metabolic Diseases, Mexico City, 1994
 Chairman: Review Section 701, Annual Meeting American Society of Nephrology, Orlando FL, 1994
 Invited Speaker: Hahneman University, Philadelphia PA, 1994
 Invited Speaker: Division of Nephrology, J.W. Goethe-University, Frankfurt, Germany, 1995
 Recipient: Chairman's Award for Excellence in Research, University of Kentucky Medical Center, 1995
 Member of Board of Directors and Invited Speaker: Advances in Mineral Metabolism, Snowmass CO, 1995
 Visiting Professor: Heinrich Heine Universität, Düsseldorf, Germany, 1995
 Invited Speaker: Satellite Symposium on Renal Bone Disease, Parathyroid Hormone, and Vitamin D, Seville, Spain, 1995
 Invited Speaker: University of Tennessee, Knoxville TN, 1995
 Invited Speaker: 8. Berliner Dialyseseminar, Berlin, Germany, 1995
 Invited Speaker: Renal Update in the 90's. Detroit MI, 1995
 Invited Speaker: Janssen-Cilag International Lectureship, Australian & New Zealand Society of Nephrology, 1996
 Invited Speaker: University of Perth, Perth, Australia, 1996
 Visiting Professor: Garvan Research Institute, Sydney, Australia, 1996
 Visiting Professor: at the Division of Nephrology and Endocrinology, University of New Zealand, Auckland, New Zealand, 1996
 Invited Speaker: Advances in Mineral Metabolism, Snowmass CO, 1996
 Co-Organizer and Chairman, International Meeting: Quality Assurance in Dialysis and Transplantation, Ulm, Germany, 1996
 Invited Lecturer: Annette Fitz Memorial Fellowship Lecture, Iowa City IA, 1996
 Invited Speaker: University of Iowa, Iowa City IA, 1996
 Invited Speaker: Georgia Rheumatology Association, Atlanta GA, 1996
 Invited Speaker: University of Modena, Italy, 1996
 Invited Speaker: Kendall Regional Medical Center, Miami FL, 1996
 Invited Speaker: University of New Jersey, New Brunswick NJ, 1996
 Invited Speaker: University of Alabama, Birmingham AL, 1996
 Invited Speaker: University of New Mexico, Albuquerque NM, 1996
 Invited Speaker: Mercy Hospital, Pittsburgh PA, 1996
 Invited Speaker: American Society for Bone and Mineral Research, Seattle WA, 1996
 Keynote Speaker: International Society of Bone Morphometry, Inc., Sardinia, Italy, 1996
 Keynote Speaker: Medical Director Advisory Board, Annual Meeting, Hilton Head SC, 1996
 Invited Speaker: American Society of Nephrology, New Orleans LA, 1996
 Invited Speaker: Mayo Clinic, Jacksonville FL, 1996
 Invited Speaker: Duke University, Durham NC, 1996
 Visiting Professor: Division of Rheumatology, Vanderbilt University, Nashville TN, January 1997
 Invited Speaker: Advanced Nephrology for the Consultant, San Diego CA, February 1997
 Visiting Professor: Texas Tech University, El Paso TX, February 1997
 Invited Speaker: Greenville Post Graduate Seminar, Greenville SC, March 1997
 Visiting Professor: University of Alabama, Birmingham AL, March 1997
 Visiting Professor: The Cleveland Clinic, Ft. Lauderdale FL, March 1997
 External Reviewer: Bone Center Day, University of Cincinnati, Cincinnati OH, March 1997
 Invited Speaker: University of Ulm, Ulm, Germany, March 1997
 Invited Speaker: University of North Carolina, Chapel Hill NC, March 1997
 Session Chairman: Advances in Mineral Metabolism, Snowmass CO, March 1997
 Visiting Professor: Duke University, Rheumatology Grand Rounds, Durham NC, 1997
 Visiting Professor: University of Medicine & Dentistry, Brunswick NJ, April 1997
 Visiting Professor: University of Tennessee, Medical Grand Rounds, Memphis TN, 1997

Invited Speaker: Columbia Presbyterian Hospital, New York NY, April 1997
 Invited Speaker: Helen Hayes Hospital, New York NY, April 1997
 Invited Speaker: Hospital for Special Surgery, New York NY, April 1997
 Invited Speaker: Osteoporosis Conference, University of Alabama School of Medicine, Huntsville AL, May 1997
 Organizing Committee and Invited Speaker: 2nd International Conference on Osteoporosis, Osaka, Japan, June 1997
 Chairman and Invited Speaker: IVth Workshop on Osteobiology, Parma, Italy, June 1997
 Visiting Professor: Vanderbilt University, Transplant Medicine Grand Rounds, Nashville TN, September 1997
 Visiting Professor: Washington University, St. Louis MO, March 1998
 Invited Speaker: The Southern Kentucky Area Health Education Center, Somerset KY, October 1998
 Invited Speaker: 31st Annual Meeting of the American Society of Nephrology, Philadelphia PA, October 1998
 Visiting Professor: University of Bern, Switzerland 1998
 Visiting Professor: Medical College of Ohio, Toledo OH, January 1999
 Invited Speaker: University of Ohio, Dayton OH, Grand Rounds, February 1999
 Visiting Professor: Columbia University, Columbia NY, Grand Rounds, March 1999
 Invited Speaker: International Pediatric Nephrology Association's Vth Symposium on Growth and Development in Children with Chronic Renal Failure, New York NY, March 1999
 Session Chairman: XIV Annual Meeting "Advances in Mineral Metabolism," Snowmass CO, April 1999
 Visiting Professor: Cleveland Clinic, Cleveland OH, April 1999
 Visiting Professor: University of Pittsburgh, Pittsburgh PA, April, 1999
 Invited Speaker: XVth International Congress of Nephrology, Buenos Aires, Argentina, May 1999.
 Invited Speaker: Symposium "Advances in the Pathogenesis and Treatment of Renal Osteodystrophy," Igaazu Falls, Argentina, May 1999
 Visiting Professor, University of Mississippi, Jackson MS, Grand Rounds, May 1999
 Visiting Professor, Vanderbilt University, Nashville TN, Transplant Program Grand Rounds, May 1999
 Invited Speaker: Tulane University, New Orleans LA, Grand Rounds, May 1999
 Invited Speaker: International Renal Osteodystrophy Symposium, Manchester, England, July 1999
 Visiting Professor: Vanderbilt University, Nashville TN, Rheumatology Grand Rounds, July 1999
 Visiting Professor: University of Ohio at Columbus, Columbus OH, Grand Rounds, July 1999
 Invited Speaker: Portsmouth, Grand Rounds for Community Physicians, July 1999
 Invited Speaker: Roanoke VA, Grand Rounds for Community Physicians, August 1999
 Invited Speaker: University of South Carolina, Charleston SC, Grand Rounds, August 1999
 Visiting Professor: University of Ohio, Dayton OH, Grand Rounds, August 1999
 Invited Speaker: University of Ohio, Columbus OH, Grand Rounds, August 1999
 Visiting Professor: Vanderbilt University, Nephrology Grand Rounds, August 1999
 Visiting Professor, Cleveland Clinic, Cleveland OH, August 1999
 Invited Speaker, University of Pennsylvania, Pittsburgh PA, Grand Rounds, September 1999
 Invited Speaker, Parkersburg WV, Grand Rounds for Community Physicians, September 1999
 Visiting Professor: University of Alabama at Birmingham, Birmingham AL, September 1999
 Visiting Professor: Grand Rounds for Community Physicians, Tuscaloosa AL, September 1999
 Invited Speaker: American Society of Bone and Mineral Research, St Louis MO, September 1999
 Invited Speaker: VIIIth Congress of the International Society of Bone Morphometry, Scottsdale AZ, October 1999
 Invited Speaker: Emory University, Atlanta GA, October 1999
 Invited Speaker: Medical College of Toledo, Toledo OH, October 1999
 Invited Speaker: Case Western University, Cleveland OH, October 1999
 Invited Speaker: Medical College of Virginia, Richmond VA, December 1999
 Invited Speaker: Georgia Rheumatology Association, Atlanta GA, December 1999
 Invited Speaker: Medicine Grand Rounds, East Carolina University, Greenville NC, January 2000
 Visiting Professor: Grand Rounds, Duke University, Durham NC, January 2000
 Visiting Professor: Grand Rounds, UNC, Greensboro NC, January 2000
 Invited Speaker: Grand Rounds, Good Samaritan Hospital, Cincinnati OH, January 2000
 Invited Speaker: Warren County Medical Society, Bowling Green KY, February 2000
 Invited Speaker: Grand Rounds, Community Hospital, Cincinnati OH, February 2000
 Invited Speaker: Grand Rounds, St. Elizabeth's Hospital, Covington KY, March 2000

Invited Speaker: University of Kentucky, Division of Orthopaedics and Sports Medicine, Lexington KY, March, 2000

Visiting Professor: Grand Rounds, Thomas Jefferson University, Philadelphia PA, March 2000

Invited Speaker: AIMM/ASBMR John Haddad Young Investigators' Meeting, Snowmass, CO, March 2000

Visiting Professor: Grand Rounds, University of Charleston Hospital, Charleston, WV, April 2000

Invited Speaker and Moderator: 9th Annual National Kidney Foundation Clinical Nephrology Meeting, Atlanta, GA, April 2000

Visiting Professor: Northeastern Ohio University College of Medicine, Gallipolis OH, April 2000

Invited Speaker, Genzyme Therapeutics Northeast Regional Physician Expert Meeting, Philadelphia PA, April 2000

Visiting Professor: University of Cincinnati, Division of Nephrology, Cincinnati OH, April 2000

Invited Speaker: Women's Health Forum, University of Kentucky, Lexington KY, May 2000

Invited Keynote Speaker: Japanese Society of Nephrology, Ngoya Japan, May 2000

Invited Speaker: Renal Network Meeting, Chicago IL, May 2000

Visiting Professor: Division of Nephrology, Harbor-UCLA Hospital and UCLA Medical Center, Los Angeles CA, May 2000

Visiting Professor: Kaiser Permanente Hospital, Los Angeles CA, May 2000

Invited Speaker: Central Regional Physician Expert Meeting, Chicago IL, June, 2000

Invited Speaker: George Washington University Hospital, Huntington WV, June 2000

Invited Speaker: Panama City Nephrology Group, Panama City FL, June 2000

Visiting Professor: University of Colorado – Denver CO, March 2001

Visiting Professor: University of Mississippi – Jackson MS, Apr 2001

Visiting Professor: University of Tennessee – Memphis TN, Apr 2001

Invited Speaker: National Kidney Foundation Annual Meeting, Orlando FL, April 2001

Invited Speaker: "Women's Health in the New Millenium" VA Employee & Education System, May 2001

Invited Speaker: Toledo Osteoporosis Society, Toledo, OH, August 2001

Invited Speaker: Thomas Jefferson University, Philadelphia, PA, September 2001

Invited Speaker: Temple University, Philadelphia, PA, October 2001

Invited Speaker: Nephrology Society of Denmark, Copenhagen, November 2001

Invited Speaker: University of Auchen, Germany, November 2001

Invited Speaker: Emory University, Atlanta, GA, January, 2002

Invited Speaker: Medical College of Virginia, Richmond, VA, March 2002

Invited Speaker: National Kidney Foundation of NY/NJ, March 2002

Invited Speaker: University Jenna, Germany, April 2002

Invited Speaker: Quebec Nephrology Society, Canada, April 2002

Invited Speaker: University of Indiana, Indianapolis, IN, May 2002

Invited Speaker: Grand Rounds, University of Cincinnati, Cincinnati, OH, June 2002

Visiting Professor: University of South Carolina, Columbia, SC, July 2002

Visiting Professor: University of Texas, Houston, TX, December 2002

Visiting Professor: Harvard University, January, 2003

Invited Speaker: International Conference on Dialysis V-Advances in ESRD, Miami Beach, FL, 2003

Visiting Professor: Yale Medical Center, 2003

Visiting Professor: New England Medical Center, 2003

Visiting Professor: University of Virginia, March, 2003

Invited Speaker: 23rd Annual Dialysis Conference, Seattle, WA, 2003

Invited Discussant: National Kidney Foundation, Washington, DC, 2003

Keynote Speaker: Finnish Society of Nephrology Annual Meeting, Helsinki, March 2003

Invited Speaker: National Kidney Foundation, Dallas, TX, April 2003

Invited Speaker: World Congress of Nephrology, Berlin, Germany, June 2003

Invited Speaker: Nephrology Quality Circle, Kassel, Germany, June 2003

Invited Speaker: International Society of Nephrology, Bamberg, Germany, June 2003

Invited Speaker: American Society of Bone and Mineral Research, Minneapolis, MN, September 2003

Invited Speaker: National Kidney Foundation, St. Simons Island, GA, September 2003

Invited Speaker: University of Miami Grand Rounds, October 2003

Invited Speaker: Swedish Society of Nephrology Annual Meeting, Stockholm, November 2003

Invited Speaker: American Society of Nephrology, San Diego, CA, November 2003

Member: NRCC Physicians' Advisory Board, January, 2004

Invited Chair: 24th Annual Conference on Peritoneal Dialysis, San Antonio, TX, February 2004
Chair and Invited Speaker: Shire Global Renal Advisory Board Meeting, Las Vegas, NV, March 2004
Invited Speaker: Shire Global Renal Advisory Board, Rome, Italy, March 2004
Invited Lecturer: University of Cambridge, April 2004
Invited Lecturer: University of Liverpool, April 2004
Invited Lecturer: Freemont Hospital, University of New Castle, April 2004
Presenter: ERA-EDTA, Lisbon, Portugal, May 2004
Invited Speaker: Grand Rounds, Haniman Hospital, Worcester, MA, June 2004
Invited Speaker: Nationaler Fortbildungs- und Referentenworkshop, Germany, June 2004
Presenter: Bone Club, Cleveland Clinic, Cleveland, OH, September 2004
Presenter: Bone Club, Case Western University, Cleveland, OH, September 2004
Invited Speaker: Grand Rounds, Cleveland Clinic, Cleveland, OH, September 2004
Chair and Invited Speaker: FDA Meeting, Bethesda, MD, September 2004
Chair: Nashville Speaker Training, Nashville, TN, October 2004
Invited Speaker: American Society of Nephrology, St. Louis, MO, October 2004
Invited Participant: Medical Crossfire Panel – ASN, St. Louis, MO, October 2004
Medicare Advisor: Medicare Meeting, Baltimore, MD, October 2004
Chair: Global Renal Advisory Board, Boston, MA, December 2004
Invited Speaker: Osteoporosis: an Evidence-Based Approach, Louisville Council of Physicians, January 2005
Visiting Professor: University of Maryland Division of Endocrinology, February 2005
Presiding Panel Member: 25th Annual Dialysis Conference, Tampa, FL, March 2005
Invited Speaker: New York Society of Nephrology, New York, NY, April 2005
Invited Speaker: Kidney & Urology Foundation of America, New York, NY, April 2005
Invited Speaker: National Kidney Foundation, Washington, DC, May 2005
Invited Speaker: 3rd World Congress of Nephrology, Singapore, June 2005
Invited Speaker: KDIGO Conference, Madrid, Spain, September 2005
Chairman and Speaker: Chronic Kidney Disease (CKD): Getting Out of the Gates Early, Lexington, KY, October 2005
Invited Speaker: Renal Bone Disease - Scientific Meeting of the Minds, New York, NY, October 2005
Invited Speaker: Nephrology Conference, Hattiesburg, MS, October 2005
Invited Speaker: American Society of Nephrology Renal Week 2005, Philadelphia, PA, November 2005
Invited Keynote: Speaker: Nephrology Experts Meeting, Munich, Germany, November 2005
Invited Lecturer: University of Tübingen, Germany, November 2005
Invited Lecturer: Medizinische Hochschule, Hannover, November 2005
Invited Keynote Speaker: 3rd Renagel Middle East Symposium, Amman, Jordan, December 2005
Invited Speaker: 18. Berliner Dialyseseminar, Berlin, Germany, December 2005
Visiting Professor: University of Graz, Austria, December, 2005
Invited Speaker: Dallas Nephrology Associates CME Conference, Dallas, TX, December 2005
Invited Speaker: Grand Rounds, Charles S. Wilson Medical School, Syracuse, NY, January 2006
Invited Speaker: Nephrology for the Consultant, San Diego, CA, February 2006
Invited Speaker: 26th Annual Dialysis Conference, San Francisco, CA, February 2006
Plenary Lecture: South African Congress of Nephrology, Cape Town, South Africa, March 2006
Invited Speaker: Janet Halkett Memorial Lecture, Cape Town, South Africa, March 2006
Invited Speaker: Bluegrass Orthopaedic Society Physician's Spring Meeting, Lexington, KY, April 2006
Invited Panelist: National Kidney Foundation - Medical Crossfire, Chicago, IL, April 2006
Invited Speaker: Grand Rounds/CME Presentation, Central Baptist Hospital, Lexington, KY, April 2006
Invited Speaker: The Dean's Clinical Research Seminar, Lexington, KY, May 2006
Invited Speaker: Nephrology Consultants Meeting, Savannah, GA, June 2006
Invited Speaker: 37th Annual Meeting, Austrian-German-Swiss Nephrology Society, Essen, Germany, September 2006
Presenter: International Society of Nephrology, NeXus Symposium, Copenhagen, Denmark, October 2006
Invited Speaker: American Society of Nephrology's Renal Week 2006, San Diego, CA, November 2006
Visiting Professor: Grand Rounds/CME Presentation, Drexel University College of Medicine, Philadelphia, PA, November 2006
Invited Speaker: Mayo Clinic, Rochester, MD, March 2007
Invited Speaker: ASN Renal Weekend, Mexico City, Mexico, March 2007

Invited Speaker: Northshore and Jewish Hospitals, New York, New York, April 2007
 Invited Speaker: Children's Hospital of Philadelphia, Philadelphia, PA, May 2007
 Invited Speaker: University of Tennessee, Memphis, TN, June 2007
 Invited Speaker: ERA/ETDA Annual Meeting, Barcelona, Spain, June 2007
 Invited Speaker: University of Southern California, Los Angeles, CA, August 2007
 Invited Speaker: University of Illinois, Chicago, IL. September 2007
 Invited Speaker: The State University of New Jersey, December 2007
 Visiting Professor: Hahnemann/Drexel University, Philadelphia, PA, December 2007
 Invited Speaker: University of Mississippi, March 2008
 Invited Speaker: University of Louisiana, March 2008
 Invited Speaker: ASN Renal Weekend, Orlando, Florida, April 2008
 Invited Speaker: University of Alabama, April 2008
 Invited Speaker: Grand Rounds, Thomas Jefferson University, Philadelphia, April 2008
 Presenter: Osteoporosis Conference for 10 Health Departments and Community Hospitals in Kentucky, University of Kentucky, Lexington, KY. April 2008
 Invited Speaker: St. Johns Medical Center, Detroit, MI, May 2008
 Invited Speaker: Grand Rounds, Nephrology Division, Penn State Hershey Medical Center, Hershey, PA, June 2008
 Moderator: American Society of Nephrology Annual Meeting, Luncheon Symposium, Managing CKD-MBD through the Disease Continuum, Philadelphia, PA., November 2008
 Moderator: American Society of Nephrology Annual Meeting, Luncheon Symposium, New Frontiers in Phosphorus Homeostasis in CKD, Philadelphia, PA., November 2008
 Moderator: American Society of Nephrology Annual Meeting, The Other Podocyte: Coming into the Spotlight, Symposium, Philadelphia, PA., November 2008
 Chairperson: American Society of Nephrology Annual Meeting, Factors Regulating Bone Remodeling, Philadelphia, PA., November 2008
 Presenter: American Society of Nephrology Annual Meeting, Usefulness of the New TMV Classification of Renal Osteodystrophy, Philadelphia, PA., November 2008
 Invited Speaker: Turkish Society of Nephrology, 25th National Congress of Nephrology, Hypertension, Dialysis and Transplantation, Antalya, Turkey, November 2008
 Invited Speaker: Shire Global Advisory Board, Chronic Kidney Disease- Mineral and Bone Disorder, New York, New York, December 2008

Professional Activity

Fellow: American College of Physicians

Member, Professional Societies:

Am. Society for Clinical Invest.	American Physiological Society
Am. Society of Nephrology	Deutsche Gesellschaft für Osteologie
Int. Society of Nephrology	EDTA—European Renal Association
Am. Soc. for Bone and Mineral Res.	Am. Fed. for Clin. Research
Endocrine Society	German Society of Internal Medicine
Central Soc. for Clin. Research	European Calcified Tissue Soc.
Int. Society of Bone Morphometry	Australian & New Zealand Society of Nephrology
Univ. of Kentucky Institutional Representative	(Honorary Member)
Am. Assoc. for the Adv. of Science	South African Renal Association (Honorary
Int. Bone and Mineral Society	Member), 2006
Orthopedic Research Society	
Am. Assoc. of University Prof.	

Founder, Past President: International Society of Bone Morphometry

Chairman, International Advisory Board: Shire Pharmaceuticals – 2004

Member, International Advisory Board: Shire Pharmaceuticals - 2006

Consultant:

Amgen Pharmaceuticals (2002-2005)

Genzyme Pharmaceuticals (2002-2005, 2007, 2008)

Chugai Pharmaceuticals (2000-2005)

FDA Advisory Committee Meeting, Shire Pharmaceuticals, Genzyme, Fresenius (2007, 2008)

Kureha Special Laboratory Co. (2007, 2008)

Editorial Board: (Past and Present)

Am. Journal of Kidney Diseases

Nephron

Mineral and Electrolyte Metabolism

Italian Jour. Min. Electrol. Metabolism

Seminars in Dialysis

American Journal of Kidney Diseases

Osteologie

Editor:

Editor-in-Chief for North, South America and Canada, Clinical Nephrology, Dustri-Verlag (1998–present)

Assoc. Editor, Clinical Nephrology, Dustri-Verlag (1996–1998)

Editor-in-Chief, Clinical Nephrology Dialysis & Transplantation, a continuously updated textbook with CD, Dustri-Verlag (1998–present)

Editor, Mediguide to Nephrology (1986, 1988)

Guest Editor:

Bone Disease in Renal Failure, in Min. Electrol. Metabolism, 1991

Bone Morphometry 1992, in Bone 1993

Nephrology at the Verge of the Century, in Kidney International, 1995

Ad hoc Reviewer for the Journals:

American Journal of Kidney Disease

American Journal of Medicine

American Journal of Pathology

Annals of Internal Medicine

Blood

Bone

Calcified Tissue International

Clinical Orthopedics

Endocrinology

Journal of the American Society
of Nephrology

Journal of Bone and Joint Surgery

Journal of Clinical Endocrinology and Metabolism

Journal of Bone and Mineral Research

Journal of Clinical Investigation

Kidney International

Lancet

Metabolism

New England Journal of Medicine

Science

Nephrology Dialysis and Transplantation

Grant Support:Government & Other Non-Industry Funding—Current

VA: Biology of IGF-1 in Bone

04/01/98-03/31/08

PI: T.L. Clemens, MD (University of Alabama at Birmingham)

Consultant Collaborators: Hartmut H. Malluche, MD; Marie-Claude Faugere, MD

Kentucky Nephrology Research Trust, Inc.

Effects of changes in serum ionized calcium on the PTH-(1-84)/PTH-(7-84) ratio in African American, Caucasian, diabetic, and non-diabetic patients on chronic maintenance dialysis.

07/01/05-06/30/09

PI: Marie-Claude Monier-Faugere, MD (University of Kentucky)

Co-investigator: Hartmut H. Malluche, MD

NIH: 1R01DK075648-01A1 Changes in Skeletal Microarchitecture Following Renal Transplantation

07/01/2006—06/30/2011

PI: Mary Leonard, MD (Children's Hospital of Philadelphia)

Consultant: Hartmut H. Malluche, MD

NIH: 1R01DK069681-01A2 Effects of pyrophosphates, and 2 bisphosphonates on vascular calcifications and bone turnover in uremic rats.

01/01/2007-12/31/2012

PI: W.C. O'Neill

Consultant: Hartmut H. Malluche, MD

ASN: 1000401244 Renal Osteodystrophy: A Fresh Approach

01/01/08-12/31/08

American Society of Nephrology M. James Scherbenske Award

PI: Hartmut H. Malluche, MD

NIH: RO1DK080770-01 Renal Osteodystrophy: A Fresh Approach

12/01/2008-11/30/2012

PI: Hartmut Malluche, MD

Co-Investigator: Marie Claude Faugere, MD

Government & Other Non-Industry Funding—PendingGovernment & Other Non-Industry Funding—Completed

NIH: RO1AM32467 Effects of Vitamin D Metabolites and PTH on Bone

9/82–8/85 – \$129,508

PI: Hartmut H. Malluche, MD

NIH: RO1AM34419 Aluminum in Bone and Muscle Abnormalities in Uremia

9/84–8/88 – \$333,314

PI: Hartmut H. Malluche, MD

Shriners Hospital for Crippled Children–

15951 Prevention of Aluminum Intoxication in Renal Osteomalacia and Rickets

1/85–12/87 – \$186,042

1/88–12/90 – \$218,627

PI: Hartmut H. Malluche, MD

Co-Investigator: Marie Claude Faugere, MD

- NIH: General Clinical Research Center
Project period: 9/1/85–3/31/06 - \$1,290,702
PI: Jay Perman, MD (University of Kentucky)
Program Director: Hartmut H. Malluche, MD (2000 – 2005)
- NIH: RO1AR35837 Bone Loss after Ovariectomy; Response to Estrogen
4/86–3/89 – \$225,743
4/91–3/95 – \$378,663
PI: Hartmut H. Malluche, MD
Co-Investigator: Marie Claude Faugere, MD
- NIH: RO1AG10836–02 (project #5)
Endocrine Calcium/Phosphate Regulation, Brain Metabolism and Alzheimer's Disease
Program Project Grant “Calcium Regulation in Brain Aging and Alzheimer's Disease”
7/92–6/97 – \$979,461
PI: Hartmut H. Malluche, MD
Co-Investigator: Robert M. Friedler, MD
- NIH: AG11098 Effect of Progestogen on Bone and Cognition in Menopause
12/1/93–2/28/01 – \$1,988,573
PI: James Liu, University of Cincinnati
Co-Investigators: Hartmut H. Malluche, MD; Marie Claude Faugere, MD
- VA Merit Review Grant: #1 K01 RR00089—01A1 Animals and Craniosynostosis
7/1/93–6/1/94 – \$431,000
PI: Janet Rodgers, DVM
Co-Investigators: Hartmut H. Malluche, MD; Marie Claude Faugere, MD; Lenn Harrison, MD
- NIH: ROIES04640 Aluminum Toxicity: Chelator Identification and Safety
6/1/94 – 5/31/95 – \$145,229
PI: Robert Yokel, MD
Co-Investigator: Hartmut H. Malluche, MD
- NIH: RO1DK51530–01 Renal Bone Disease
8/15/96–7/31/06 – \$1,298,672
P.I. Hartmut H. Malluche, MD
- NIH: Bone Growth and rhBMP-2: Immediate and Sustained Release Balance
12/1/98-11/30/00 -- \$49,983
PI: Henry C. Vasconez, MD
Co-Investigators: Hartmut H. Malluche, MD; Patrick P DeLuca, Ph.D.

Industry Funded—Completed

- Shire Pharmaceuticals -- Effects of Lanthanum Carbonate Compound with Calcium Carbonate on Renal Bone Disease in Chronic Renal Failure Patients Receiving Dialysis
11/00 - 2005
PI: Hartmut H. Malluche, MD
- Amgen Inc. – Effects of an Oral Calcimimetic Agent on Renal Bone Disease in Hemodialysis Patients with Secondary Hyperparathyroidism
3/02–3/05 – \$119,000
PI: Hartmut H. Malluche, MD
- GelTex Pharmaceuticals/Genzyme Europe – Effects of Sevelamer Hydrochloride & Calcium Carbonate on Bone Turnover & Mineralization in Hemodialysis Patients
6/02–2005 – \$280,000
PI: Hartmut H. Malluche, MD

Clinical Fellows Supervised

Clifford Matthews, MD
 Thomas H. Waid, MD
 Marek Kacki, MD
 Pat Angelos, MD
 Clara Womack, MD
 Greg Robbins, MD
 Anil Mehta, MD
 Mosta Haque, MD
 Ramesh Boothapuri, MD
 Ismo Kaarininen, MD
 Steve McCullough, MD
 Harold Helton, MD
 Ana Lia Castellanos, MD
 Kevin Harned, MD
 Aziz Chami, MD

Marco Costa, MD
 Ayman Bakleh, MD
 Tariq Muhammed, MD
 Taofik Babalakin, MD
 Mark Bates, MD
 Adnan Maqsood, MD
 Imad Khdair, MD
 Akinlolu O. Ojo, MD
 Piti Ratapaninich, MD
 John Shepherd, MD
 Bindu Pavithran, MD
 Mony Fraer, MD
 Bill Barrett, MD
 Stephen Chalmers, MD
 Sunil Agrawal, MD

Hanna Mawad, MD
 Muhammad Uddin, MD
 Jide Babalakin, MD
 Patrick Kulubya, MD
 R. Pat Sabo, MD
 Ravi Sarin, MD
 Rezkalla Butros, MD
 Ajmal Shamim, MD
 Shahzeb Naqvi, MD
 Ziad Sara, MD
 David Trueba, MD
 Clint Edwards, MD
 Bill Pence, MD
 James Michael Francis, MD

Postdoctoral and Faculty Trainees

Marie–Claude Faugere, MD
 Associate Research Professor
 Department of Internal Medicine
 University of Kentucky, Lexington, KY
 Graduate, University of Marseilles, Marseilles, France

Paolo Fanti, MD
 Assistant Professor
 Department of Internal Medicine
 University of Kentucky, Lexington, KY
 Graduate of University of Bologna, Bologna, Italy

Ilkka Arnala, MD
 Associate Professor of Orthopedic Surgery
 Graduate, Kuopio University, Kuopio, Finland

Thomas J. Wronski, PhD
 Associate Professor
 Department of Physiological Sciences
 Graduate, University of Florida, Gainesville, FL

Benedek Bogнар, MD
 Research Fellow/Consultant Radiologist
 Graduate, Semmelweis Medical University,
 Budapest, Hungary

Chinghua Yao
 Research Assistant
 Institute of Pediatrics
 Tianjin Children's Hospital, Kunming City, China

Shao–xing Wu, MD
 Physician of Nephrology
 Graduate, Sun Yat–Sen University, Guangzhou, China

Nabil Abdalla Maksoud, MD, PhD
 Vice Director of National Poison Center
 A. Professor, Faculty of Medicine
 Cairo University
 Cairo, Egypt

Yahya Subayti, MD
 Research Fellow
 Graduate, American University, Beirut, Lebanon

Juergen Klein, MD
 Research Fellow
 Abteilung Nephrologie
 Graduate, Universitaetsklinik Ulm, Deutschland

Robert Juvin, MD
 Research Fellow
 Graduate, University of Grenoble, France

Robert Letton
 UK–Dean’s Research Fellowship
 Department of Surgery
 Graduate, Bowman Gray School of Medicine

Dr. Zhaopo Geng
 Research Fellow
 Graduate, Tianja, PR China

Pauling Chu, MD, PhD
 Director of Dialysis Center, Division of Nephrology
 Tri-Service General Hospital
 National Defense Medical Center
 Taipei, Taiwan

Elsie Barr, MS
 Technologist
 University of Kentucky, Lexington, KY

Janet Rodgers, DVD
 Research Professor of Plastic Surgery
 University of Kentucky, Lexington, KY

Terry Horn, PhD
 Department of Biomechanics
 Lexington, KY

William Shieh, MD
 Chief of Nephrology Division
 Graduate, Tri–Service General Hospital
 Taipei, Taiwan

Miguel Lapuz, MD
 Assistant Professor
 Division of Nephrology,
 Marshall University, WV

Chris Langub, PhD
 Scientific Review Administrator
 Office of Extramural Programs
 National Institute for Occupational Safety & Health

Stefan Kiessling, MD
 Special Faculty
 Department of Pediatrics Nephrology
 University of Kentucky, Lexington, KY.

Hanna Mawad, MD
 Associate Professor
 Director, Dialysis Services
 Division of Nephrology, Bone and Mineral Metabolism
 University of Kentucky, Lexington, KY

Joon S. Lee, MD, Ph.D
 Division of Nephrology, Dept. of Internal Medicine
 Gachon University
 Gill Medical Center
 Guwol-dong, Namdon-gu, Incheon
 Republic of Korea

PhD Dissertation Mentor Program

Nabil Abdalla Maksoud, MD, PhD
 Vice Director of National Poison Center
 A. Professor, Faculty of Medicine
 Cairo University
 Cairo, Egypt

Pauling Chu, MD, PhD
 Director of Dialysis Center, Division of Nephrology
 Tri-Service General Hospital
 National Defense Medical Center
 Taipei, Taiwan

Daniel S. Porter, MS
 PhD Candidate
 Center for Biomedical Engineering
 University of Kentucky, Lexington, KY

Masters Degree Thesis Mentor Program

Johann Herberth, MD
 Assistant Professor
 Division of Nephrology, Bone and Mineral Metabolism
 University of Kentucky, Lexington, KY

Thomas H. Waid, MD, MS
 Professor of Internal Medicine
 Division of Nephrology, Bone and Mineral Metabolism
 University of Kentucky, Lexington, KY

Other Creative Activity

U.S. Patent: "Method of Treating Alzheimer's Disease".

U.S. Patent, European Patent, South African Patent, and Australia Patent: "Method for Rapid Embedding and Processing of Tissue Samples for Histology".

Monographs

1. MALLUCHE HH: Skeletthistologische Befunde bei Niereninsuffizienz, Habilitationsschrift, J.W. Goethe Universitaet, Frankfurt, 1975.
2. MALLUCHE HH and Faugere M-C: Atlas of Mineralized Bone Histology, New York and Basel, S. Karger, 1986.

Publications – Journals and Books (peer-reviewed articles are printed in bold)

3. Frey J, MALLUCHE HH: Ueber Konzentrationsleistungen kranker Nieren in Aktuelle Probleme der Dialyseverfahren and Niereninsuffizienz, edited by Dittrich and Skrabal, Bindernagel, Friedberg, pp. 367–371, 1971.
4. Schoeppe W, Oppermann F, MALLUCHE HH, Shaldon S, Koch KM: Bericht ueber zweijaehrige Erfahrungen in der Routinebehandlung der chronischen Uraemie durch Heimdialyse in Aktuelle Probleme der Dialyseverfahren and Niereninsuffizienz, edited by Dittrich and Skrabal, Bindernagel, Friedberg, pp. 34–40, 1971.
5. Ritz E, Krempien B, MALLUCHE HH: Quantitative Bone Histology after Dialysis with High Calcium Concentrations in the Dialysate and after Vitamin D Therapy in Rein et Calcium, Les Trois Epis, pp. 256–258, 1972.
6. MALLUCHE HH: The Value of Bone Biopsies for Diagnosis of Renal Bone Disease in Dialysis Transplantation Nephrology ("Can renal bone disease be prevented" panel) edited by Moorhead JR, Baillood RA, Mion C, London, Pitman Medical, 1973, pp. 111–115.
7. Ritz E, Krempien B, Mehls O, MALLUCHE HH: Skeletal Abnormalities in Chronic Renal Insufficiency Before and During Maintenance Hemodialysis. **Kidney Int** 4: pp. 116–127, 1973.
8. Ritz E, Krempien B., Mehls O, MALLUCHE HH, Strobel A, Zimmermann H: Skeletal complications of renal insufficiency and maintenance hemodialysis. **Nephron** 10: pp. 195–207, 1973.
9. Ritz E, MALLUCHE HH, Roehrer HD, Krempien B, Koch KM, Andrassy K: Aktuele Probleme der subtotalen Parathyreoidektomie bei Haemodialysepatienten. **Dtsch Med Wschr** 98: pp. 484–496, 1973.
10. MALLUCHE HH, Ritz E, Koch KM, Krempien B, Schoeppe W: Verhalten der Skeletthistologie bei uraemischer Osteodystrophie nach Erhoehung der Dialysatcalcium-Konzentration auf 3,75 mval/l in Verh. Dtsch. Ges., Inn. Med, Berlin–Heidelberg, Springer, 1973, Vol. 79, pp. 720–731.
11. Fassbinder W, Reitinger W, Huegel E, Koch KM, Lange HP, MALLUCHE HH, Schroeder HM: Konservative und operative Therapie des Goodpasture-Syndrome in Verh. Dtsch. Ges., Inn. Med, Berlin–Heidelberg, Springer, 1973, Vol. 79, pp. 703–706.
12. MALLUCHE HH, Schoeppe W, Koch KM, Lange HP: Osteopathie bei chronischer Niereninsuffizienz. **Deutsches Aerzteblatt** 70: pp. 2025–2032, 1973.

13. Andrassy K, MALLUCHE HH, Bornefeld H, Comberg M, Ritz E, Jesdinsky H, Moehring M: Prevention of p.o. clotting of av Cimino fistulae with acetysalicyl acid. Results of prospective double blind study. **Klin Wschr** 52: pp. 348–352, 1974.
14. Ritz E, MALLUCHE HH, Bommer J, Mehls O, Krempien B: Metabolic bone disease in patients on maintenance hemodialysis. **Nephron** 12: pp. 393–404, 1974.
15. MALLUCHE HH: Prophylaxe und Therapie der azotaemischen Osteopathie. **Kassenarzt** 10: pp. 1666–1670, 1974.
16. MALLUCHE HH, Klempa I, Hodgson M, Feuerle G, Koch KM: Serumgastrinspiegel and Magensaftsekretion beim chronischer Haemodialysepatienten und ihre Beeinflussung durch Aenderungen des ionisierten Serum-CA in **Verh. Dtsch. Ges., Inn. Med, Berlin–Heidelberg, Springer, 1974, Vol. 80, pp. 690–692.**
17. Lange HP, MALLUCHE HH, Arras D: Die Entwicklung der renalen Osteopathie unter chronischer Haemodialysebehandlung bei bilateral nephrektomierten skelettgesunden Patienten. **Verh. Dtsch. Ges., fuer Pathologie** 58: pp. 366–370, 1974.
18. Ritz E, Bommer J, Krempien B, Mehls O, MALLUCHE HH: Diagnostische Moeglichkeiten zur Erfassung der Uraemischen Osteopathie. VI Symposium der Europaeischen Gesellschaft fuer Osteoarthrologie. edited by Prof. Dr Dominok, 1974, pp. 80–82.
19. MALLUCHE HH, Ritz E, Hodgson M, Kutschera J, Krause G, Seiffert U, Gati A, Lange HP: Skeletal lesions and calcium metabolism in early renal failure in **Dialysis, Transplantation, Nephrology, Proc Europ Dial Transpl Assn, 1974, pp. 443–450.**
20. Ritz E, Krempien B, Prager P, Bommer J, Mehls O, MALLUCHE HH: Knochenveraenderungen bei chronischer Niereninsuffizienz. **Med Klinik** 70: pp. 1112–1124, 1975.
21. Zebe H, Vollrath P, Ritz E, Bommer J, Vetter W, MALLUCHE HH, Bundschu HD: Psychologische und somatische Analyse der Potenzstoerung bei uraemischen und nierentransplantierten Patienten in **Aktuelle Probleme der Dialyseverfahren und der Niereninsuffizienz, edited by P. Dittrich and F. Skrabal, Friedberg/Hessen, Bindernagel–Friedberg, 1975, pp. 448–459.**
22. MALLUCHE HH, Ritz E, Lange HP, Krempien B, Bommer G, Schoeppe W: In welchem Stadium der Niereninsuffizienz beginnt der Hyperparathyreoidismus und die Osteomalazie? in **Aktuelle Probleme der Dialyseverfahren und der Niereninsuffizienz, edited by P. Dittrich and F. Skrabal, Friedberg/Hessen, Bindernagel, 1975, pp. 506–515.**
23. MALLUCHE HH, Ritz E, Kutschera J, Krause K, Werner E, Gati A, Seiffert U, Lange H.P: Calcium metabolism and impaired mineralization in various stages of renal insufficiency in **Vitamin D and Problems Related to Uremic Bone Disease, edited by Norman, Schaefer, Grigoleit, Herrath, Ritz, Berlin–New York, Walter de Gruyter, 1975, pp. 513–522.**
24. Werner E, MALLUCHE HH, Kutschera J, Hodgson M, Schoeppe W: Intestinal calcium absorption and whole-body calcium retention in various stages of renal insufficiency in **Calcified Tissues 1975 edited by P. Nielson and H. Hansen, Copenhagen, Fadls Forlag, 1975, pp. 210–215.**
25. Ritz E, Mehls O, MALLUCHE HH, Krempien B, Schmidt–Gayd H, Heimberg H: Unanswered problems in uremic bone disease in **Vitamin D and Problems Related to Uremic bone disease, edited by Norman, Schaefer, Grigoleit, Herrath, Ritz, Berlin–New York, Walter de Gruyter, 1975, pp. 497–512.**
26. MALLUCHE HH, Ritz E, Lange, HP, Kutschera K, Hodgson M, Seiffert U, Schoeppe W: Bone histology in incipient and advanced renal failure. **Kidney Int** 9: pp. 355–362, 1976.
27. MALLUCHE HH, Ritz E, Lange HP, Arras D, Schoeppe W: Bone mass in maintenance hemodialysis. Prospective study with sequential biopsies. **Europ J Clin Invest** 6: pp. 265–271, 1976.
28. MALLUCHE HH, Ritz E, Lange HP, Schoeppe W: Changes of bone histology during maintenance hemodialysis at various levels of dialysate Ca concentration. **Clin Nephrol** 6: pp. 440–447, 1976.
29. MALLUCHE HH, Ritz E: Sekundaerer Hyperparathyreoidismus bei Niereninsuffizienz. Prophylaxe and Therapie. **Muench Med Wschr** 118: pp. 129–130, 1976.

30. Vollrath P, Ferner H, Vetter P, Ritz E, Zebe H, Bundschu HD, MALLUCHE HH: Sexual behavior of patients undergoing maintenance dialysis. *Inn Med* 3: pp. 349–356, 1976.
31. Ritz E, Bommer J, MALLUCHE HH: Calciumhaushalt bei Nierenerkrankungen in *Klinik des Wasser-, Elektrolyt- and Saeure-Basen-Haushalts* edited by H. Zumkley, Stuttgart, George Thieme Verlag, 1977, pp. 239–244.
32. Prager P, Ritz E, Bommer J, Krempien B, MALLUCHE HH, Schnurr H: Wert and Grenzen der Roentgen-Skelettdiagnostik bei renaler Osteopathie; histologisch-roentgenologische Vergleichsuntersuchungen in *Nephrologie in Klinik and Praxis*, Vol. 4, Muenchen, Dustri Verlag, 1977, pp. 109–117.
33. MALLUCHE HH, Fassbinder W, Hodgson M, Schoeppe W, Koch KM: Probleme der Behandlung des sekundaeren Hyperparathyreoidismus bei Haemodialyse-Patienten in *Nephrologie in Klinik and Praxis*, Vol. 4, Muenchen, Dustri Verlag, 1977, pp. 155–161.
34. MALLUCHE HH, Ritz E, Werner E, Meyer WA: The effect of vitamin D steroles on bone histology in incipient renal failure in *Vitamin D, Biochemical, Chemical and Clinical Aspects related to Calcium Metabolism* edited by AW Norman, K. Schaefer, JS. Coburn, Berlin-New York, Walter de Gruyter, 1977, pp. 407–409.
35. MALLUCHE HH, Ritz E: Experimentelle Untersuchungen zur Parathormon-Resistenz des Skeletts bei Niereninsuffizienz. *Verh. Dtsch. Ges., Inn. Med* 83: pp. 1302–1305, 1977.
36. Werner E, MALLUCHE HH, Ritz E: Intestinale Calciumabsorption im Fruehstadium der Niereninsuffizienz und ihre Beeinflussung durch 5.6-trans-25-OHCC *Verh. Dtsch. Ges., Inn. Med* 83: pp. 1305–1307, 1977.
37. Ritz E, MALLUCHE HH, Krempien B, Mehls O: Bone histology in renal insufficiency in *Calcium Metabolism in Renal Failure and Nephrolithiasis* edited by S.D David, New York, J Wiley and Sons, 1977, pp. 197–233.
38. MALLUCHE HH, Werner E, Ritz E: Intestinal absorption of calcium and whole-body calcium retention in incipient and advanced renal failure. ***Min Electrol Metab*** 1: pp. 263–270, 1978.
39. Ritz E, Prager P, Krempien B, Bommer J, MALLUCHE HH, Schmidt-Gayk H: Skeletal X-ray findings and bone histology in patients on hemodialysis. ***Kidney Int*** 13: pp. 316–323, 1978.
40. MALLUCHE HH, Ritz E, Werner E, Meyer-Sabellek WA: Long-term administration of vitamin D sterols in incipient and advanced renal failure: effect on bone histology. ***Clin Nephrol*** 10: pp. 219–228, 1978.
41. Ritz E, MALLUCHE HH, Krempien B, Tschoepe W, Massry SG: Pathogenesis of renal osteodystrophy: roles of phosphate and skeletal resistance to PTH in *Homeostasis of Phosphate and Other Minerals* edited by Massry SG, Ritz E, Rapado, A, Plenum Publishing Corp., 1978, pp. 423–436.
42. Goldstein DA, Massry SG: Management of renal osteodystrophy with 1,25(OH)₂D₃. I. Effects on clinical, radiographic and biochemical parameters. ***Min Electrol Metab*** 2: pp. 35–47, 1979.
43. MALLUCHE HH, Goldstein DA, Massry SG: Management of renal osteodystrophy with 1,25(OH)₂D₃. II. Effects of histopathology of bone; evidence for healing of osteomalacia. ***Min Electrol Metab*** 2: pp. 48–55, 1979.
44. MALLUCHE HH, Goldstein DA, Massry SG: Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. ***J Clin Invest*** 63: pp. 494–500, 1979.
45. Ritz E, Krempien B, MALLUCHE HH: Evaluation of histological procedures in the investigation of bone disease related to vitamin D in *Vitamin D-Basic Research and its Clinical Application* edited by Norman AW, Schaefer K., Herrath DV., Grigoleit HG, Coburn JW, DeLuca HF., Mawer EB, Suda T, Berlin-New York, Walter De Gruyter, 1979, pp. 907–912.
46. MALLUCHE HH, Henry H, Meyer WA, Sherman, D, Massry SG, Norman AW: Effects and interaction of 1,25(OH)₂D₃ and 24.25(OH)₂D₃ on bone in *Vitamin D-Basic Research and Its Clinical Application* edited by Norman AW, Schaefer K., Herrath DV, Grigoleit HG, Coburn JW, DeLuca HF, Mawer EB, Suda T, Berlin-New York, Walter De Gruyter, 1979, pp. 425–427.

47. Tschoepe W, Pohl J, Brenner R, MALLUCHE HH, Meyer-Sabellek W, Ritz E: Knochenhistologie bei idiopathischer Hypercalciurie in Pathogenese und Klinik der Harnsteine VII edited by Gasser G, Vahlensiek V, Steinkopff D, Verlag-Darmstadt, 1979, pp. 141–146.
48. Tschoepe W, Pohl J, Brenner R, MALLUCHE HH, Ritz E: Knochenhistologie bei absorptive Hypercalciurie in Verh Dtsch, Ges, Inn Med, vol. 85 edited by Bergmann JF, Verlag-Muenchen, 1979, pp. 639–642.
49. MALLUCHE HH, Tschoepe W, Ritz E, Meyer-Sabellek W, Massry SG: Abnormal bone histology in idiopathic hypercalciuria **J Clin Endocrin Metab** 50: pp. 654–658, 1980.
50. MALLUCHE HH, Henry H, Meyer-Sabellek W, Sherman D, Massry SG, Norman AW: Effects and interaction of $24T,25(OH)_2D_3$ and $1,25(OH)_2D_3$ on bone. **Am J Physiol** 238: pp. E494–E498, 1980.
51. Norman AW, Henry HL, MALLUCHE HH: $24R,25$ -dihydroxyvitamin D_3 and $1,25$ -dihydroxyvitamin D_3 are both indispensable for calcium and phosphorus homeostasis. *Life Sci* 27: pp. 229–237, 1980.
52. Healy MD, MALLUCHE HH, Goldstein DA, Singer FR, Massry SG: Effects of long-term therapy with calcitriol in patients with moderate renal failure. **Arch Intern Med** 14: pp. 1030–1033, 1980.
53. Siede WH, Seiffert UB, Bundschuh F, MALLUCHE HH, Schoeppe W: Alkaline phosphatase bone isoenzyme activity in serum in various degrees of micromorphometrically assessed renal osteopathy. **Clin Nephrol** 13: pp. 277–281, 1980.
54. MALLUCHE HH, Meyer-Sabellek W, Singer FR, Massry SG: Evidence for a direct effect of thiazide on bone. **Min Electrol Metab** 4: pp. 89–96, 1980.
55. Massry SG, Goldstein DA, MALLUCHE HH: Current status of the use of $1,25(OH)_2D_3$ in the management of renal osteodystrophy. **Kidney Int** 19: pp. 409–418, 1980.
56. MALLUCHE HH, Goldstein DA, Massry SG: Effects of 6 months therapy with $1,25(OH)_2D_3$ on bone disease of dialysis patients in Uses and Actions of $1,25$ -dihydroxyvitamin D_3 in Uremia Contributions to Nephrology edited by Berlyne GM. et al., Basel, S Karger, 1980, pp. 98–104.
57. MALLUCHE HH, Massry SG: The role of vitamin D metabolites in the management of bone abnormalities in renal disease in Homeostasis of Phosphate and Other Minerals edited by Massry SG, Ritz E, John J, Plenum Publishing Corp., 1980, pp. 15–624.
58. Goldstein DA, MALLUCHE HH, Massry SG: Long-term effects of $1,25(OH)_2D_3$ on clinical and biochemical derangements of divalent ions in dialysis patients in Contributions to Nephrology edited by Berlyne GM. et al., Basel, S Karger, 1980, pp. 2–54.
59. Manaka RC, MALLUCHE HH: A program package for quantitative analysis of histologic structure and remodeling dynamics of bone. *Comput Programs BioMed* 13: pp. 191–202, 1981.
60. MALLUCHE HH, Tschoepe W, Meyer W, Ritz E, Massry SG: Disturbed terminal mineralization of bone in idiopathic hypercalciuria in Urolithiases—Clinical and Basic Research edited by Smith LH Robertson WG, Finlayson B, New York-London, Plenum Publishing Corp., 1981, pp. 841–845.
61. MALLUCHE HH, Sherman D, Meyer WA, Henry H, Norman AW, Massry SG: Comparison of vitamin D_3 and various metabolites in experimental rickets in Bone Histomorphometry edited by Jee WSS, Parfitt AM., Paris, SN.PM.D, 1981, pp. 375–378.
62. MALLUCHE HH, Sherman D, Manaka R, Massry SG: Comparison between different histomorphometric methods in Bone Histomorphometry edited by Jee WSS, Parfitt, AM., Paris, SN.PM.D, 1981, pp. 449–451.
63. Ritz E, MALLUCHE HH, Krempien B, Mehls O: Calcium metabolism in renal failure in Disorders of Mineral Metabolism edited by Bronner F, Coburn, J, New York, Academic Press, 1981, pp. 151–250.
64. Massry SG, MALLUCHE HH, Goldstein DA, Schoeppe W: Influence of long-term hemodialysis on uremic bone disease in Uremia: Pathobiology of Patients Treated for 10 Years or More edited by Giordano C, Friedman, EA, Milano, Wichtig Editore, 1981, pp. 73–82.
65. Werner E, Roth P, Malluche HH: Anwendung des Gankorperzahlers bei Untersuchungen zum Calciumstoffwechsel, in *Medizinische Physik*, edited by Bunde E. (Hrsg), Heidelberg, Huthig, 1981.

66. MALLUCHE HH, Sherman D, Meyer W, Massry SG: A new semiautomatic method for quantitative static and dynamic bone histology. **Calcif Tissue Int** 34: pp. 439–448, 1982.
67. MALLUCHE HH, Meyer W, Sherman D, Massry SG: Quantitative bone histology in 84 normal American subjects. Micromorphometric analysis and evaluation of variance of iliac bone. **Calcif Tissue Int** 34: pp. 449–455, 1982.
68. MALLUCHE HH, Sherman D, Meyer W, Ritz E, Norman AW, Massry SG: Effects of long-term infusion of physiologic doses of 1–34 PTH on bone. **Am J Physiol** 242: pp. F197–F201, 1982.
69. MALLUCHE HH, Akmal, M, Mayer E, Norman A, Massry SG: Parathyroid hormone reverses effects of 1,25(OH)₂ Vitamin D on bone dynamics in Vitamin D, Chemical, Biochemical and Clinical Endocrinology of Calcium Metabolism, Berlin–New York, Walter de Gruyter & Co., pp. 539–544, 1982.
70. Faugere M.C., MALLUCHE HH: Comparison of different bone biopsy techniques for qualitative and quantitative diagnosis of metabolic bone diseases. **J Bone Joint Surg** 65A: pp. 1314–1319, 1983.
71. MALLUCHE HH, Faugere MC: Bone mineral accretion and dissolution in Hypercalciuria States: Pathogenesis, Consequences and Treatment edited by Coe FL., New York, Grune & Stratton, Inc, pp. 143–203, 1983.
72. Dorr LD, Lindberg JP, Faugere MC, MALLUCHE HH: Factors influencing the intrusion of methylmethacrylate into human tibiae. **Clin Orthop** 132: pp. 147–152, 1984.
73. Ritz E, MALLUCHE HH: Renale Osteopathie. **Internistische Welt**. 7: pp. 204–235, 1984.
74. Smith AJ, Tate M, Stelling CB, Doukas M, Mitchell B, MALLUCHE HH: Recurrent fractures, hypophosphatemia and renal insufficiency in an elderly woman. **Am J Nephrol** 4: pp. 329–335, 1984.
75. Wyatt RJ, Julian BA, Scott EC, Bhatena DB, Mitchell BL, Block FJ, Holland NH, MALLUCHE HH: IgA nephropathy: Presentation, clinical course and prognosis in children and adults. **Am J Kidney Dis** 4: pp. 192–200, 1984.
76. MALLUCHE HH, Smith AJ, Abreo K, Faugere MC: The use of desferrioxamine in the management of renal patients with bone aluminum accumulation. **N Engl J Med** 311: pp. 140–144, 1984.
77. MALLUCHE HH, Faugere MC, Fanti P, Price PA: Plasma levels of bone Gla–protein reflect bone formation in patients on clinic maintenance dialysis. **Kidney Int** 26: pp. 869–874, 1984.
78. Faugere MC, Abreo K., Smith A, MALLUCHE HH: Bone aluminum accumulation: Etiology, prevalence and its influences on vitamin D therapy in patients with mild to advanced renal failure in Endocrine Control of Bone and Calcium Metabolism, Elsevier Science Publishers BV, pp. 151–152, 1985.
79. MALLUCHE HH, Faugere MC: Evaluation of different biopsy techniques for qualitative and quantitative histology of bone in Endocrine Control of Bone and Calcium Metabolism, Elsevier Science Publishers BV, pp. 351–353, 1985.
80. Freundlich M, Zilleruelo G, Arbitbol C, Strauss J, Faugere MC, MALLUCHE HH: Infant formula as a cause of aluminum toxicity in neonatal uremia **Lancet** II: pp. 527–529, 1985.
81. MALLUCHE HH, Faugere MC: Aluminum: toxin or innocent bystander in renal osteodystrophy? **Am J Kidney Dis** 6: pp. 336–341, 1985.
82. MALLUCHE HH, Faugere MC, Smith AJ, Friedler RM: Aluminum intoxication of bone in renal failure: fact or fiction? **Kidney Int** 29, S18: pp. 70–73, 1986.
83. Faugere MC, Okamoto S, DeLuca HF, MALLUCHE HH: Calcitriol corrects bone loss induced by oophorectomy in rats. **Am J Physiol** 13: pp. 35–38, 1986.
84. MALLUCHE HH, Faugere MC, Ritz E, Caillens G, Wildberger D: Endogenous calcitonin does not protect against hyperparathyroid bone disease in renal failure. **Min Electrol Metab** 12: pp. 113–118, 1986.

85. MALLUCHE HH, Faugere MC: Renal osteodystrophy in Mediguide to Nephrology, Vol. 1, New York, Dellacorte Publishers, pp. 1–8, 1986.
86. Fanti P, Smith AJ, Price PA, Reitz RE, MALLUCHE HH: Effects of parathyroidectomy on circulating levels of 1,25–dihydroxy–vitamin D and bone Gla–protein in dialyzed patients. **J Clin Endocrin Metab** 62: pp. 869–873, 1986.
87. Faugere MC, Arnala I, Ritz E, MALLUCHE HH: Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis. **J Lab Clin Med** 107: pp. 481–487, 1986.
88. Smith AJ, Faugere MC, Abreo K., Fanti P, Julian B, MALLUCHE HH: Aluminum related bone disease in mild and advanced renal failure. **Am J Nephrol** 6: pp. 275–283, 1986.
89. Faugere MC, MALLUCHE HH: Stainable aluminum and not aluminum content reflect histologic changes in bone of dialyzed patients. **Kidney Int** 30: pp. 717–722, 1986.
90. MALLUCHE HH, Matthews C, Faugere MC, Fanti P, Friedler RM: 1,25–Dihydroxyvitamin D maintains bone cell activity, and parathyroid hormone modulates bone cell number in dogs. **Endocrinology** 119: pp. 1298–1304, 1986.
91. Freundlich M, Abitbol C, Faugere MC, Zilleruelo G, Strauss J, MALLUCHE HH: Treatment of aluminum toxicity with deferoxamine in infantile uremia **J Pediatr** 109: pp. 140–143, 1986.
92. MALLUCHE HH, Faugere MC, Rush M, Friedler RM: Osteoblastic insufficiency is responsible for maintenance of osteopenia after loss of ovarian function. **Endocrinology** 119: pp. 2649–2654, 1986.
93. MALLUCHE HH, Matthews C, Faugere MC, Fanti P, Friedler RM: Parathyroid hormone in 1,25 Vitamin D₃ exert opposite effects on bone in Phosphate and Mineral in Homeostasis edited by Massry SG, Olmer M, Ritz E Plenum Publishing Corp., pp. 289–290, 1986.
94. MALLUCHE HH, Smith AJ: Unraveling mixed renal osteodystrophy. A CPC Series: Cases in Metabolic Bone Disease, The Rogosin Institute, Education in Practice, 1986.
95. MALLUCHE HH, Faugere MC, Fanti P, Friedler RM: Calcitriol, parathyroid hormone and the accumulation of aluminum in bone in dogs with renal failure. **J Clin Invest** 79: pp. 754–761, 1987.
96. Friedler RM, MALLUCHE HH: The effects of diuretics on renal calcium excretion. Mediguide to Nephrology, Vol. 1, New York, DellaCorte Publishers, pp. 1–8, 1987.
97. MALLUCHE HH, Faugere MC: Renal bone disease in Internal Medicine, Section 4, Chapter 317, edited by Stein J, Boston, Little Brown & Co., pp. 2118–2123, 1987.
98. Julian BA, Faugere MC, MALLUCHE HH: Oxalosis in bone causing a radiographic mimicry of uremic osteodystrophy. **Am J Kidney Dis** 9(5): pp. 436–440, 1987.
99. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, MALLUCHE HH, Meunier, PJ, Ott SM, Recker RR: Bone histomorphometry: Standardization of nomenclature, symbols, and units. **J Bone Miner Res** 6: pp. 595–610, 1987.
100. MALLUCHE HH, Faugere MC: Aluminum related bone disease. **Blood Purifications** 1–15, 1988.
101. MALLUCHE HH, Faugere MC, Friedler RM, Fanti P: 1,25–Dihydroxyvitamin D₃ corrects bone loss but suppresses bone remodeling in ovariohysterectomized beagle dogs. **Endocrinology** 122: pp. 1998–2006, 1988.
102. MALLUCHE HH, Faugere MC: The cellular basis of aluminum bone disease and its relationship to vitamin D metabolism in Nephrology – Proceedings of the Xth International Congress of Nephrology, edited by Davison AM, London, Balliere Tindall, WB Saunders, 1988, pp. 1082–1085.
103. Kanis JA, Thavarajah M, Evans D, Norman AW, Horst RL, Uskokovic M, Drezner MK, MALLUCHE HH: Prospects for the modeling of vitamin D activity in man in Vitamin D – Molecular, Cellular and Clinical Endocrinology, edited by Norman AW, Schaefer K, Grigoleit H–G, Herrath DV, Walter de Gruyter Publishers, pp. 739–750, 1988.
104. Abreo K, MALLUCHE HH: The effect of 1,25 vitamin D and parathyroidectomy on the uptake of aluminum in bone of rats with renal insufficiency. **Am J Nephrol** 8:426–430, 1988.

105. MALLUCHE HH, Faugere MC, Arnala I: Noninvasive techniques for predicting bone histology. **Ann Chirurgiae et Gynaecologiae** 77: pp. 246–250, 1988.
106. Baker LRI, Abrams, SML, Roe, CJ, Faugere MC, Fanti P, Subayti Y, MALLUCHE HH: 1,25(OH)₂D₃ administration in moderate renal failure: A prospective double–blind trial. **Kidney Int** 35: pp. 661–669, 1989.
107. MALLUCHE, HH, Faugere MC: Therapy of aluminum related bone disease in Clinical Disorders of Bone and Mineral Metabolism edited by Kleerekoper M, Krane ST., New York, Liebert Publishers, 1989, pp. 597–601.
108. Baker LRI, Abrams, L, Roe, CJ, Faugere MC, Fanti P, Subayti Y, MALLUCHE HH: Early therapy of renal bone disease with calcitriol: A prospective double–blind study. **Kidney Int** 36, Suppl. 27: pp. 140–142, 1989.
109. MALLUCHE HH, Faugere MC: Renal osteodystrophy. **New Engl J Med** 321: pp. 317–319, 1989.
110. MALLUCHE HH, Faugere MC: Letter to the editor **New Engl J Med** 321:P. 1833, 1989.
111. MALLUCHE HH, Faugere MC: Renal bone disease in Internal Medicine, Section 4, Chapter 317, edited by Stein J, Boston, Little Brown & Co. Third Edition, 1989, pp. 2368–2372.
112. MALLUCHE HH, Faugere MC: The value of desferal infusion test for diagnosis of aluminum bone disease in patients with end stage renal failure in Aluminum and Iron Overload in Hemodialysis edited by DeBroe ME, Hogrefe & Huber Publishers, Toronto, Lewiston, NY, Bern, Göttingen, Stuttgart, pp. 11–15, 1989.
113. Bia MJ, Cooper K, Schnall S, Duffy T., Hendler E, MALLUCHE HH, Solomon L: Aluminum induced anemia: Pathogenesis and treatment in patients on chronic hemodialysis. **Kidney Int** 36: pp. 852–858, 1989.
114. Dunlay RW, Camp M, Allon M, MALLUCHE HH, Fanti P, Llach F: The role of calcitriol in prolonged hypocalcemia due to tumor lysis syndrome. **Ann Int Med** 110: pp. 162–164, 1989.
115. Faugere MC, Friedler RM, Fanti P, MALLUCHE HH: Bone changes occurring early after cessation of ovarian function in beagle dogs: a histomorphometric study employing sequential biopsies. **J Bone Miner Res** 5(3): pp. 263–272, 1990.
116. MALLUCHE HH: Histologie der renalen Osteopathie in Renale Osteopathie, edited by Malluche HH, Franz HE, Wissenschaftliche Verlagsgesellschaft mbh Stuttgart 1990, pp. 79–84 and 106–115.
117. MALLUCHE HH, Faugere MC: Role of calcitriol in the management of osteoporosis. **Metabolism** 33: pp. S24–26, 1990.
118. MALLUCHE HH, Faugere MC: Bone biopsies: histology and histomorphometry of bone in Metabolic Bone Disease edited by Avioli LV, Krane SM, WB Saunders Co., pp. 283–328, 1990.
119. MALLUCHE HH, Faugere MC: Renale Osteopathie in Blutreinigungsverfahren, edited by Franz HE, Georg Thieme Verlag, Stuttgart, pp. 277–296, 1990.
120. MALLUCHE HH, Faugere MC: Renal bone disease 1990: An unmet challenge for the nephrologist. **Kidney Int** 38: pp. 193–211, 1990.
121. MALLUCHE HH, Faugere MC: Effects of 1,25(OH)₂D₃ administration on bone in patients with renal failure. **Kidney Int** 38, Suppl. 29: pp. S48–53, 1990.
122. Letton RW, Fanti P, MALLUCHE HH: Regulation of 25(OH)D metabolism in cultures of osteoblastic cells. **J Bone Miner Res** 5(8): pp. 815–823, 1990.
123. Baker L, Rose C, Abrams L, Faugere MC, Fanti P, Subayti Y, MALLUCHE HH: Administration of 1,25(OH)₂D₃ in patients with mild to moderate renal impairment corrects hyperparathyroid–related bone disease, but reduces bone turnover in Bone Morphometry, Proceedings of the Fifth International Congress on Bone Morphometry, edited by Takahashi H, Smith–Gordon, Nishimura, pp. 290–294, 1990.

124. Dorr LD, Arnala I, Faugere MC, MALLUCHE HH: Preoperative systemic bone disease: Five year postoperative results of cemented femoral arthroplasty. *Clin Orth Rel Res* 259: pp. 114–121, 1990.
125. MALLUCHE HH, Faugere MC, Baker LRI: Prevention of bone disease in renal failure in *Prevention in Nephrology*, edited by deBroe ME, Verpooten GA, Kluwer Academic Publishers, pp. 73–78, 1991.
126. John J, MALLUCHE HH, Kerschbaumer F, Thoma W: Wirbelkörperkompressionsfraktur bei aluminiuminduzierter Osteopathie nach langjähriger Antazida-Medikation *in Osteologie–interdisziplinär*, edited by Werner E, Matthiass HH, Springer-Verlag, Berlin-Heidelberg, pp. 417–420, 1991.
127. MALLUCHE HH, Faugere MC: Vitamin D₃ and uremic bone disease *in Nephrology*, Vol. I edited by Hatano M, Springer-Verlag, Tokyo, pp. 450–454, 1991.
128. MALLUCHE HH, Bognar B, Friedler RM, Faugere MC: 1,25R,26 (OH)₃-22 ene D₃, A novel therapeutic agent for reversal of bone loss associated with cessation of ovarian function *in Vitamin D–Gene Regulation Structure–Function Analysis and Clinical Application* edited by Norman AW, Bouillon, R Thomasset, M, Berlin, Walter de Gruyter & Co., pp. 537–538, 1991.
129. MALLUCHE HH: Aluminium-Knochenerkrankung: Diagnose und Therapie *in Dialyse 1991*, edited by Franz HE, Stuttgart, Wissenschaftliche Verlagsgesellschaft mbh, pp. 93–98, 1991.
130. MALLUCHE HH, Faugere MC: Uremic bone disease: Current knowledge, controversial issues and new horizons. **Miner Elec Metab** 17: pp. 281–296, 1991.
131. MALLUCHE HH: Guest Editor, Bone Disease in Renal Failure; Introduction. **Miner Elec Metab** 17: pp. 209–210, 1991.
132. MALLUCHE HH, Faugere MC, Bognar B, Friedler RM: 1,25,26 D₃ — A novel therapeutic agent for reversal of bone loss associated with cessation of ovarian function. *Proceedings 8th Workshop on Vitamin D*, Paris, 1991.
133. MALLUCHE HH: Renale Osteopathie – Eine Indikation fuer Bisphosphonate *in Innovative Aspekte der klinischen Medizin* edited by Koch HM, Rosenthal J, Fleisch H, Scigalla P, Heidelberg, Springer-Verlag, pp. 98–105, 1992.
134. MALLUCHE HH: Diagnostik aluminiumbedingter Knochenerkrankungen bei Patienten mit Niereninsuffizienz *in: Desferrioxamine–Geschichte, Stellenwert und Perspektiven*, MMW Medizin Verlag, pp. 77–81, 1992.
135. MALLUCHE HH, Faugere MC: Risk of adynamic bone disease in dialyzed patients. *Kidney Int* 42 No. 4 (Suppl. 38): pp. 62–67, 1992.
136. MALLUCHE HH: Diagnosis of aluminum bone disease in patients with renal failure in: *Desferrioxamine—History, Clinical Value, Perspectives*, edited by Gross K, Aumiller J, Gelzer J, MMW Medizin Verlag, pp. 69–73, 1992.
137. Ott MT, Fanti P, MALLUCHE HH, Ryo UY, Whaley FS, Strodel WE, Colacchio TA: Biochemical evidence of metabolic bone disease in women following the roux–y gastric bypass for morbid obesity. *Obesity Surgery* 2: pp. 341–348, 1992.
138. Fanti P, Kindy M, Mohapatra S, Klein J, Colombo G, and MALLUCHE HH: Dose-dependent effects of aluminum on osteocalcin synthesis in osteoblast-like ROS 17/2 cells in culture. **Am J Physiol** 263: pp. E1113–E1118, 1992.
139. MALLUCHE HH: The possible use of bisphosphonates in the treatment of renal osteodystrophy. *Clin Nephrol* 38: pp. S87–S91, 1992.
140. MALLUCHE HH: Effects of Calcitriol in Renal Bone Disease, in *Update and Consensus on the Management of Renal Osteodystrophy*. Abbott Laboratory, Renal Care. N. Chicago, IL. Editor: Edwardo Slatopolsky pp. 8–10, Jan. 1993.
141. Metsger DS, Arnala I, Faugere MC, MALLUCHE HH: Histomorphometric analysis of tricalcic phosphate ceramic implanted into turkeys. **Bone** 14: pp. 243–248, 1993.

142. Rodgers JB, Faugere MC, MALLUCHE HH: Animal models for the study of bone loss after cessation of ovarian function. **Bone** 14: pp. 369–377, 1993.
143. Tsukamoto Y, Mariyo R, Nomura Y, Sato N, Faugere MC, MALLUCHE HH: Long-term effects of oral Calcitriol pulse therapy on bone in hemodialysis patients. **Bone** 14: pp. 421–424, 1993.
144. Dorr L, Faugere M–C, Mackel A, Gruen T, Bogner B, MALLUCHE HH: Structural and cellular assessment of bone quality of proximal femoral. **Bone** 14: pp. 231–242, 1993.
145. John J, MALLUCHE HH, Faugere MC, Thoma W, Kerschbaumer F: Compression fracture of a vertebral body after long-term ingestion of aluminum-containing antacid medication. *Osteologie Band 2, Heft 1*: pp. 41–45, 1993.
146. Fanti P, Colombo G, Yao C, Brown SA, Vernon MW, MALLUCHE HH: Development and characterization of a polyclonal antiserum-based radioimmunoassay for dog osteocalcin. **J Bone Min Res** 8: pp. 745–752, 1993.
147. Colombo G, Fanti P, Yao C, MALLUCHE HH: Isolation and complete amino acid sequence of osteocalcin from canine bone. **J Bone Min Res** 8: pp. 733–743, 1993.
148. Klein J, MALLUCHE HH: Renale Osteopathie in *Dialyse für Krankenpflegeberufe*, edited by HE Franz, Thieme Verlag, 1993, pp. 227–240.
149. MALLUCHE HH, Klein J: Aluminuminduzierte Osteopathia in *Dialyse für Krankenpflegeberufe*, edited by HE Franz, Thieme Verlag, 1993, pp. 241–244
150. Sawaya PB, MALLUCHE HH: Renal osteodystrophy is a multifaceted disease with no uniform therapy. **Seminars in Dialysis** 6: pp. 210–214, 1993.
151. MALLUCHE HH: Renal Osteodystrophy–Diagnosis. Proceedings of the Second Annual Spring Clinical Nephrology Meetings of the National Kidney Foundation, Inc, 1993, pp. 164–168.
152. Agarwal S, Goodman NL, MALLUCHE HH: Peritonitis due to *Exophiala Jeanselme* in a patient undergoing continuous ambulatory peritoneal dialysis. **Am J Kid Dis** 21: pp. 673–675, 1993.
153. MALLUCHE HH, Faugere MC: Renal bone disease in *Internal Medicine, Section 9, 4th Edition*, edited by Stein, J, Boston, Little Brown Co., 1993, Chapter 186, pp. 2802–2811.
154. Monier–Faugere MC, Friedler RM, Bauss F, MALLUCHE HH: A new bisphosphonate, BM21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. **J Bone Min Res** 8 (11): pp. 1345–1355, 1993.
155. MALLUCHE HH, Monier–Faugere MC Mechanisms of bone loss after cessation of ovarian function–therapeutic implications (Übersichtsreferat) in *Osteologie aktuell VII* edited by HJ Pesch, H Stoss, B Kummer, Springer–Verlag, Berlin, 1993, pp. 405–409.
156. Kurz P, Faugere M–C, Roth P, Werner E, Vlachojuannis J, MALLUCHE HH, Grützmacher P. Differenzierung der renalen Osteopathie mit Hilfe kalziumkinetischer Parameter in *Osteologie aktuell VII* edited by HJ Pesch, H Stoss, B Kummer, Springer–Verlag, Berlin, 1993, pp. 488–491.
157. MALLUCHE HH. Neue Aspekte der Pathogenese und Klinik der renalen Knochenerkrankung in *Aktuelle Nephrologie für Nephrologen in Klinik and Praxis*, edited by HE Franz, Wissenschaftliche Verlagsgesellschaft mbh Stuttgart, 1993, pp. 11–16.
158. McMurtry C, Godschalk M, MALLUCHE HH, Geng Z, Adler R. Oncogenic Osteomalacia Associated with Metastatic Prostate Carcinoma: Case Report and Review of the Literature, *J Am Ger Soc*, 1993, pp. 983–985.
159. MALLUCHE HH, Rodgers JB: Animal models for osteoporosis in *Sex Steroids and Bone* edited by R Ziegler, J Pfeilschifter, and M Bräutigam, Springer–Verlag, Berlin, 1994, pp. 151–166.
160. MALLUCHE HH, Faugere MC: The Role of Bone Biopsy in the Management of Patients with Renal Osteodystrophy. **J Amer Soc Nephrol**, 4, No. 9, pp. 1641–1642, 1994.
161. Klein J, MALLUCHE HH: Renal Osteopathie, in *Klinische Nephrologie, Handbuch für Klinik und Praxis*, Herausgeber: HE Franz, T Risler, ECOMED–Verlag Landsberg/Lech, pp. 1–10, 1994.

162. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachoianis J, MALLUCHE HH: Calcium kinetics in patients with renal osteodystrophy. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. **Kidney Int** 46: pp. 855–861, 1994.
163. Monier-Faugere MC, MALLUCHE HH: Calcitriol pulse therapy in patients with end-stage renal failure. *Current Science* 3: pp. 615–619, 1994.
164. Briner VA, Thiel G, Monier-Faugere MC, Bognar B, Landmann J, Kamber V, and MALLUCHE HH: Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation. **Transplantation** 59: (10): pp. 1393–1400, 1995.
165. MALLUCHE HH: Renal bone disease – an ongoing challenge to the nephrologist. *Clin Nephrol* 44: (1): pp. S36–S39, 1995.
166. MALLUCHE HH, Sawaya P, Faugere MC: Dialysis: Current status, contemporary limitations and future challenges. *Kidney Int* 48: pp. S37–S39, 1995.
167. MALLUCHE HH. Renal bone disease 1982–1984: Continued need for bone biopsies. *Mediguide to Nephrology* 3(1): pp. 1–8, 1995.
168. Sawaya P, MALLUCHE HH. Parathyroid hormone, vitamin D and metabolic bone disease in dialysis patients. *Clinical Dialysis*, 3rd edition, edited by Nissenson, Fine & Gentile, Appleton & Lange, pp. 744–776, 1995.
169. Qi Q, Faugere MC, Geng Z, MALLUCHE HH. Predictive value of serum parathyroid levels for bone turnover in patients on chronic maintenance dialysis. **Am J Kid Dis** 26: (4): pp. 622–631, 1995.
170. Faugere MC, Geng Z, Qi Q, Arnala I, MALLUCHE HH. Calcitonin prevents bone loss but decreases osteoblastic activity in ovariectomized beagle dogs. **J Bone Min Res** 11(4): pp. 446–455, 1996.
171. Liu SM, Koszewski NH, Olivera A, Lapus MH, MALLUCHE HH. Characterization of a response element in the 5'-flanking region of the avian parathyroid hormone gene that mediates negative regulation of gene transcription by 1,25-dihydroxyvitamin D3 and binds the vitamin D receptor. **Mol Endocrinol** 10: pp. 206–215, 1996.
172. Monier-Faugere MC, MALLUCHE HH. Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. **Nephrol Dial Transplant** 11(3): pp. 111–120, 1996.
173. Langub MC, Koszewski NJ, Turner HV, Monier-Faugere MC, Geng Z and MALLUCHE HH: Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. **Kidney Int** 50 (2): pp. 515–520, 1996.
174. Klein J, MALLUCHE HH: Renale Osteopathie. *Dialyse für Pflegeberufe*: pp. 243–257, 1996.
175. Klein J, MALLUCHE HH: Aluminiuminduzierte Osteopathie. *Dialyse für Pflegeberufe*: pp. 257–260, 1996.
176. Sawaya BP, Koszewski NJ, Q Qi, Langub MC, Monier-Faugere MC, MALLUCHE HH: Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure. **J Am Soc Nephrol** 8 (2): pp. 271–278, 1997.
177. Rastogi S, MALLUCHE HH. Understanding and management of hypo- and hypercalcemia. *Mediguide to Nephrology* 5 (3), 1997.
178. Monier-Faugere MC, MALLUCHE HH. Role of cytokines in renal osteodystrophy. *Current Opinion in Nephrology and Hypertension* 6(4): pp. 327–332, 1997.
179. MALLUCHE HH, Monier-Faugere MC; Renal bone disease in *Internal Medicine*, Section 9, Chapter 186, 5th Edition, edited by Stein, J., Boston, Little Brown & Co., Fifth Edition, pp. 1961–1965, 1997.
180. Szejnfeld VL, Monier-Faugere MC, Bognar, BJ, Ferraz MB, MALLUCHE HH: Systemic osteopenia and mineralization defect in patients with ankylosing spondylitis. **J Rheumatol** 24: pp. 683–688, 1997.
181. Fanti P, Monier-Faugere MC, Geng Z, Schmidt J, Cohen D, MALLUCHE HH. Moderately high consumption of ethanol suppresses histologic parameters of bone resorption in ovariectomized but not in sexually intact adult female rats. *Alcohol Clin Exp Res* 2(6): pp. 1150–1154, 1997.

182. Pienkowski ., Doers TM, Monier–Faugere M.C, Geng Z, Camacho NP, Boskey AL, MALLUCHE HH: Calcitonin alters bone quality in beagle dogs. **J Bone Miner Res** 12: pp. 1936–1943, 1997.
183. MALLUCHE HH, Monier–Faugere MC: Bone biopsies: a modern approach in *Metabolic Bone Disease* edited by Avioli, L.V., and Krane, S.M., WB Saunders Co., Third Edition, pp. 237–273, 1997.
184. MALLUCHE HH, Langub MC, Monier–Faugere MC: Pathogenesis and histology of renal osteodystrophy. *Osteoporosis Int* 7(Suppl 3): pp. S184–S187, 1997.
185. Koszewski NJ, Reinhardt TA, Langub MC, MALLUCHE HH, Horst RL: Selectivity of a C–terminal peptide antiserum for different DNA–binding states of the vitamin D receptor. *Arch Biochem Biophys* 349(2): pp. 388–396, 1998.
186. Fanti P, Monier–Faugere MC, Geng Z, Schmidt J, Morris PE, Cohen D, MALLUCHE HH: The phytoestrogen genistein reduces bone loss in short–term ovariectomized rats. **Osteoporosis Int** 8: pp. 274–281, 1998.
187. Monier–Faugere MC, MALLUCHE HH: Mineralized bone histology in the normal and uremic state in *Renal Osteodystrophy*, edited by Bushinsky, D.A., Philadelphia, Lippincott, Raven, 1998, pp. 49–87.
188. Monier–Faugere, M.C., Geng, Z., Friedler, R.M., Qi, Q., Kubodera, N., Slatopolsky, E., MALLUCHE HH: 22–Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure **Kidney Int** 55: pp. 821–832, 1999.
189. Monier–Faugere, M.C., Geng, Z., Paschalis, L., Qi, Q., Arnala, I., Bauss, F., Boskey, A.L., MALLUCHE HH: Intermittent and continuous administration of the bisphosphonate ibandronate in ovariectomized beagle dogs: effects on bone morphometry and mineral properties. **J Bone Miner Res** 1999; 14: pp. 1768–1778.
190. Mawad, H.W., Sawaya, B.P., MALLUCHE HH: Calcific uremic arteriolopathy in association with low turnover uremic bone disease. **Clin Nephrol** 52: pp. 160–166, 1999.
191. MALLUCHE HH, Monier–Faugere MC: Understanding and managing hyperphosphatemia in patients with chronic renal disease. **Clin Nephrol** 52: pp. 267–277, 1999.
192. MALLUCHE HH, Langub, M.C., Monier–Faugere, M.C.: The role of bone biopsy in clinical practice and research. *Kidney Int* 73: pp. S20–S25, 1999.
193. Rastogi, S., MALLUCHE HH: The dyscalcemias: hypocalcemia and hypercalcemia in *Current Therapy in Nephrology and Hypertension*, edited by Glasscock, R.J., Mosby Yearbook, Fourth edition, pp. 17–25, 1998.
194. Monier–Faugere, M.C., MALLUCHE HH: Renal osteodystrophy in *Cecil Textbook of Medicine*, edited by Goldman L, Bennett JC, Philadelphia, W.B. Saunders, Twenty–First Edition, pp. 1409–1414, 2000.
195. Pienkowski, D., Doers, T.M., Maitra, R., Monier–Faugere, M–C., MALLUCHE HH: BMD and the mechanical competence of bones in the canine skeleton. **Osteologie** 8(4): pp. 186–194, 1999.
196. Monier–Faugere, M.C., Sawaya, B.P., MALLUCHE HH: Renal osteodystrophy in *Clinical Nephrology, Dialysis and Transplantation*, edited by Malluche HH, Sawaya, B.P., Hakim, R.M., Sayegh, M.H., Munich, Dusti–Verlag, pp. II–8, 1999.
197. Koszewski N.J., MALLUCHE HH, Russell J.: Vitamin D receptor interactions with positive and negative response elements: an interference footprint comparison. *J Steroid Biochem Mol Biol* 72: pp. 125–132, 2000.
198. Monier–Faugere MC, Mawad H, Qi Q, Friedler R, MALLUCHE HH: High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. **J Am Soc Nephrol** 11: pp. 1093–1099, 2000.
199. MALLUCHE HH, Mawad H: Beurteilung und Behandlung von Hyperphosphatämie bei Patienten mit chronischer Niereninsuffizienz. *Nieren-und Hochdruckkrankheiten* 29: pp. 159–170, 2000.
200. Geng Z, Monier–Faugere MC, Bauss, F, MALLUCHE HH: Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. **Clin Nephrol** 54(1): pp. 45–53, 2000.

201. Geng Z, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike, JW, Chernausek SD, Rosen CJ, Donahue, L-R, MALLUCHE HH, Fagin JA, Clemens TL: Targeted overexpression of insulin-like growth factor 1 to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. **Endocrinology** 141(7): pp. 2674–2682, 2000.
202. Langub M.C., Faugere M.C., MALLUCHE H.H.: Molecular bone morphometry. **Pediatr Nephrol** 14: pp. 629–635, 2000.
203. Langub MC, Reinhardt TA, Horst RL, MALLUCHE HH, Koszewski NJ: Characterization of vitamin D receptor immunoreactivity in human bone cells. **Bone** 27(3): pp. 383–387, 2000.
204. MALLUCHE HH, Monier–Faugere M–C: Hyperphosphatemia: pharmacologic intervention yesterday, today and tomorrow. **Clin Nephrol** 54(4): pp. 309–317, 2000.
205. Langub M.C., Monier–Faugere M.C., Qi Q, Koszewski N.J., MALLUCHE HH: PTH/PTHrP receptor in human bone. **J Bone Miner Res** 16(3): pp. 448-456, 2001.
206. Langub MC, Herman JP, MALLUCHE HH, Koszewski NJ. Evidence of functional vitamin D receptors in rat hippocampus. **Neuroscience** 104(1): pp. 49-56, 2001.
207. Monier-Faugere M-C, Geng Z, Mawad H, Friedler R, Gao P, Cantor T, MALLUCHE HH: Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. **Kidney Int** 60: pp. 1460-1468, 2001.
208. Ashman, N, MALLUCHE HH, Cunningham J: Hypercalcemia and human nature. **Clin Nephrol** 55: pp. 327-330, 2001
209. Koszewski, NJ, Kiessling, S, MALLUCHE HH. Isolation of Genomic DNA Sequences that Bind Vitamin D Receptor Complexes. *Biochem and Biophys Research Communications*. **Biochem Biophys Res Commun** 283: pp. 188-194, 2001.
210. Kimmel PL, Langman CB, Bogner B, Faugere M–C, Chawla LS, Watkins DW, MALLUCHE HH: Zinc nutritional status modifies renal osteodystrophy in uremic rats. **Clin Nephrol** 56: pp. 445-58, 2001.
211. MALLUCHE HH, Mawad H: Management of hyperphosphatemia of chronic kidney disease: Lessons from the past and future directions. **Nephrol Dial Transplant** 17: pp. 1-6, 2002.
212. MALLUCHE HH, Mawad, H, Koszewski NJ: Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. **Kidney Int** 62: pp. 367-374 2002.
213. MALLUCHE HH: Aluminum and bone disease in chronic renal failure. **Nephrol Dial Transplant** 17: pp. 21-24, 2002.
214. Langub, MC, MALLUCHE HH: Parathyroid hormone type 1 receptor and human osteoclasts. **J Bone Miner Res** 17: p. 1916, 2002.
215. MALLUCHE HH, Faugere MC, Koszewski NJ: Use and Indication of Vitamin D and Vitamin D Analogues in Patients with Renal Bone Disease. *Nephrol Dial Transplant* 2002; 17 Suppl 10: pp. 6-9.
216. Monier-Faugere MC, Sawaya BP, Langub MC, MALLUCHE HH: Bone – Normal Structure and Physiology *in* *Calcium in Internal Medicine*, edited by Morii H, Nishizawa Y, Massry SG, Springer Verlag London: pp. 309-321, 2002.
217. Monier–Faugere MC, Langub MC, MALLUCHE HH: Bone biopsy in patients with renal failure *in* *Textbook of Nephrology*, edited by Massry SG, Glassock RJ, Baltimore, Williams and Wilkins, 2002.
218. Zhang M, Xuan S, Bouxein ML, Von Stechow D, Akeno N, Faugere MC, MALLUCHE HH, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL: Osteoblast-specific knockout of the IGF receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. **J Biol Chem** 277(46): pp. 44,005-44,012, 2002.
219. Langub MC, Monier-Faugere MC, Wang G, Williams JP, Koszewski NJ, MALLUCHE HH. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on Bone in Rats with Moderate Renal Failure. **Endocrinology** 144(4): pp. 1135-1138, 2003.

220. MALLUCHE HH, Mawad H: Letter to the Editor (Management of hyperphosphatemia of chronic kidney disease: lessons from the past and future directions.) **Nephrol Dial Transplant** 18(4): pp. 848-9, 2003.
221. MALLUCHE HH, Mawad H, Trueba D, Monier-Faugere M-C: Parathyroid hormone assays—evolution and revolutions in the care of dialysis patients. **Clin Nephrol** 59(5): pp. 313-318, 2003.
222. MALLUCHE HH, Monier-Faugere MC: PTH-(1-84), PTH fragments and bone turnover. **Am J Kidney Dis** 41(5): pp. 1127, 2003.
223. Zhang M, Faugere MC, MALLUCHE HH, Rosen CJ, Chernausk SV, Clemens TL: Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice decreases bone turnover and causes global growth retardation. **J Bone Min Res** 18(5): pp. 836-43, 2003.
224. Alimov AP, Langub MC, MALLUCHE HH, Koszewski, NJ: Sp3/Sp1 in the parathyroid gland: identification of an Sp1 deoxyribonucleic acid element in the parathyroid hormone promoter. **Endocrinology** 144(7): pp. 3138-47, 2003.
225. Sawaya BP, Butros R, Naqvi S, Geng Z, Mawad H, Friedler R, Fanti P, Monier-Faugere MC, MALLUCHE HH: Differences in bone turnover and intact PTH levels between African-American and Caucasian patients with end-stage renal disease. **Kidney Int** 64(2): pp. 737-42, 2003.
226. Trueba D, Sawaya BP, Mawad H, MALLUCHE HH: Bone biopsy: indications, techniques, and complications. *Semin Dial* 16(4): pp. 341-5, 2003.
227. MALLUCHE HH, Koszewski NJ: Letter to the Editor (Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure.) **Kidney Int** 63: pp. 1586, 2003.
228. Coco, M, Glicklich, D, Burris, L, Bogнар, I, Tellis, V, Greenstein, S, Schechner, R, Wang, G, Faugere, MC, MALLUCHE HH: Prevention of bone loss in renal transplant recipients: A prospective randomized trial of intravenous pamidronate. **J Am Soc Nephrol** 14(10): pp. 2669-76, 2003.
229. Monier-Faugere, MC, MALLUCHE HH: Renal osteodystrophy *in* Cecil Textbook of Medicine, 22nd ed., edited by Goldman L, Bennett JC, Philadelphia, W.B. Saunders, 2003.
230. MALLUCHE HH, Mawad H, Monier-Faugere, MC, The importance of bone health in end-stage renal disease: out of the frying pan into the fire? **Nephrol Dial Transplant** 2004 Mar; 19 Suppl 1: pp. i9-13.
231. Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, MALLUCHE, HH, McCarthy JT, Massry SG, Mehls O, Salushky IB, Silver JM, Smogorzewski MT, Slatopolsky EM, McCann L; Bone Turnover Work Group: Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. **Am J Kidney Dis** 43(3): pp. 558-65, 2004.
232. Alimov AP, Langub MC, MALLUCHE HH, Park-Sarge OK, Koszewski NJ. Contrasting Mammalian PTH Promoters: NF-Y Binds to a DNA Element Unique to the Human PTH Promoter and Acts as a Transcriptional Enhancer. **Endocrinology** 145(6): pp. 2713-20, 2004.
233. Alimov, AP, Park-Sarge, OK, MALLUCHE HH, Koszewski, NJ. GenBank, Accession AY728082, Transcription Factor Binding Sites in the Rat Parathyroid Hormone Promoter, Sept. 27, 2004.
234. Koszewski NJ, Alimov AP, Park-Sarge OK, MALLUCHE HH. Suppression of the Human Parathyroid Hormone Promoter by Vitamin D Involves Displacement of NF-Y Binding to the Vitamin D Response Element. **J Biol Chem** 2004 Oct 8; 279(41): pp. 42431-7.
235. Monier-Faugere MC, MALLUCHE HH. Histologic Abnormalities of Bone before and after Kidney Transplantation *in* Bone Disease of Organ Transplantation, edited by Compston J, Shane E, Elsevier Academic Press: pp.243-254, 2005.
236. Freemont, T, MALLUCHE HH. Utilization of Bone Histomorphometry in Renal Osteodystrophy: Demonstration of a New Approach Using Data from a Prospective Study of Lanthanum Carbonate. **Clin Neph** 63(2): pp. 138-145, 2005.
237. Koszewski NJ, Alimov AP, Langub MC, Park-Sarge OK, MALLUCHE HH. Contrasting mammalian PTH promoters: identification of transcription factors controlling PTH gene expression. **Clin Neph** 63(2): pp. 158-162, 2005.

238. Alimov AP, Park-Sarge OK, Sarge KD, MALLUCHE HH, Koszewski NJ. Transactivation of the parathyroid hormone promoter by Sp proteins and the nuclear factor Y complex. **Endocrinology** 2005 Aug 146(8): pp. 3409-16.
239. Botolin S, Faugere MC, MALLUCHE HH, Orth M, Meyer R, McCabe LR. Increased bone adiposity and PPAR γ 2 expression in Type I diabetic mice. **Endocrinology** Aug 146(8):3622-31, 2005.
240. Martin KJ, Masafumi F and MALLUCHE HH. Diagnosis of Bone and Mineral Disorders in KDIGO Clinical Guide to Bone and Mineral Metabolism in CKD. Editor Klaus Olgaard. National Kidney Foundation, pp. 45-73, 2006.
241. MALLUCHE HH, Monier-Faugere MC. Renal Osteodystrophy: What's in a Name? Presentation of a clinically useful new model to interpret bone histologic findings. **Clin Neph** 65(4): pp. 235-242, 2006.
242. Herberth J, Fahrleitner-Pammer A, Obermayer-Pietsch B, Krisper P, Holzer H, MALLUCHE HH and Dobnig H. Changes in total parathyroid hormone (PTH), PTH-(1-84) and large C-PTH fragments in different stages of chronic kidney disease. **Clin Neph** 65(5): pp. 328-334, 2006.
243. MALLUCHE HH, Koszewski NJ, Monier-Faugere MC, Williams JP, Mawad H. Influence of the Parathyroid Gland on Bone Metabolism. **Eur J Clin Invest** 36 (Suppl 2): pp. 23-33, 2006.
244. Lin Y-L, de Villiers WJS, Garvy B, Post SR, Nagy TR, Safadi FF, Faugere MC, Wang G, MALLUCHE HH, Williams JP. The Effect of Class A Scavenger Receptor (SR-A) Deficiency in Bone. **J Biol Chem** 282 (7), 4653-4660, 2007.
245. Andress DL, MALLUCHE HH, Sprague SM. Bone and Mineral Metabolism in CKD. Medical Crossfire, special edition 8(4): pp. 1-19, 2007.
246. Finn WF and MALLUCHE HH. Regulation of Phosphate in Health and Disease. Johns Hopkins University: Advanced Studies in Medicine 7(5): pp. 133-139, 2007.
247. Middleton JP and MALLUCHE HH. Bone Complications and Calcification of Soft Tissues in Chronic Kidney Disease. Johns Hopkins University: Advanced Studies in Medicine 7(5): pp. 140-145, 2007.
248. Porter GA and MALLUCHE HH. Treatment Options in the Management of Phosphate Retention. Johns Hopkins University: Advanced Studies in Medicine 7(5): pp. 146-151, 2007.
249. Faugere MC, Mawad H, MALLUCHE HH. Opposite Effects of Calcitriol and Paricalcitol on the PTH-(1-84)/Large Fragments ratio in Patients with Chronic Kidney Disease Stage-5. **Clin J Am Soc Neph** vol. 2(6):pp. 1255-60, 2007.
250. Herberth J, Alimov A, Williams J, MALLUCHE HH, Koszewski N. Parathyroid hormone regulation of the human cytomegalovirus immediate-early gene promoter. **Bio and Bioph Research Comm**, vol. 368/4: pp. 977-982, 2008.
251. Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, MALLUCHE HH. Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystrophy in Hemodialysis Patients. **J Am Soc Neph** 19: 405-412, 2008.
252. MALLUCHE HH, Monier-Faugere MC, Wang G, Frazao JM, Charytan C, Coburn, JW, Coyne DW, Kaplan Baker N, McCary LC, Turner SA, Goodman WG. An assessment of cinacalcet HCL effects on bone histology in dialysis patients with secondary hyperparathyroidism, **Clinical Nephrology** 69(4): 269-277, 2008.
253. MALLUCHE HH, Mawad H, Monier-Faugere MC. Bone biopsy in patients with osteoporosis. **Current Osteoporosis Reports**, 5(4); 146-52, 2008.
254. Nieminen J, Sahlman J, Hirvonen T, Lapveteläinen T, Hume EL, Miettinen M, Arnala I, Ala-Kokko L, MALLUCHE HH, Helminen KJ. Disturbed synthesis of type II collagen interferes with rate of bone formation and growth and increases bone resorption in transgenic mice. **Calcified Tissue International**, 82(3): pp. 229-337, 2008.

255. Fahrleitner-Pammer A, Herberth J, Browning S, Obermayer-Pietsch B, Wirnsberger G, Holzer H, Dobnig H, MALLUCHE HH. Bone Markers Predict Cardiovascular Events in Chronic Kidney Disease. **J Bone Min Res**, 23(11); 1850-1858, 2008.
256. MALLUCHE HH, Monier-Faugere MC, Mawad H. Effects of treatment of renal osteodystrophy on bone histology. **Clin J Am Soc Neph**, 3; S157-S163, 2008.
257. MALLUCHE, HH, Siami G, Swanepoel C, Wang, G, Mawad HW, Confer S, Smith M, Pratt R, Faugere MC. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. **Clin Nephrol**, 70(4); 284-296, 2008.
258. Adragao T, Herberth J, Monier-Faugere MC, Branscum A, Ferreira A, Frazao J, Curto J, MALLUCHE HH. Low Bone Volume – A Risk Factor for Coronary Calcifications in Hemodialysis Patients. **Clin J Am Soc Neph**, 4: 450-455, 2009.
259. Lomashvili K, MALLUCHE HH, Monier-Faugere MC, O'Neill C. Effect of Bisphosphonates on Vascular Calcification and Bone Metabolism in Renal Failure. **Kidney Int.**, online publication, January 2009.

Publications In Press/Submitted

1. Monier-Faugere MC, Koszewski N, Wang G and MALLUCHE HH. PTH (7-84) Induces Increased Intact PTH Levels and Increased Number But Decreased Activity of Osteoblasts in Experimental Rats. **Submitted, JBMR.**
2. H.Fehmi, Y. Osman, S. Bhat, K. Nguyen, O. Daramola, T. Cantor, M.-C. Monier-Faugere, J.Yee, and HH MALLUCHE: Absence of Adynamic Bone Disease in African Americans with CKD Stage 5 after 3 Year of Vitamin D Therapy Guided by iPTH and the PTH-(1-84)/N-Terminally Truncated PTH Fragments Ratio. **In press, Clin Nephrol.**
3. Moore C, Adams E, Rao D, Daramola-Ogunwuyi, O, Fehmi H, Bhat S, MALLUCHE HH, Monier-Faugere M, Yee J, Osmo-Malik Y. Relationship of Bone Histology to Markers of Bone and Mineral disease in Prevalent African-American Hemodialysis Patients. **Submitted, CJASN, 2008.**
4. N Koszewski, MALLUCHE HH. Retinoic acid receptor gamma 2 interactions with vitamin D response elements. **Submitted, December 2008.**
5. Herberth J, Monier-Faugere MC, Mawad H, Branscum A, Wang G, Herberth Z, Cantor T, MALLUCHE HH. Bone Turnover Assessment by the 5 Most Commonly Used iPTH Assays. **Submitted, CJASN 2009.**
6. Adragao, T. Herberth, J. Monier-Faugere MC, Branscum A, Ferreira A, Frazao J, MALLUCHE HH. Femoral Bone Mineral Density Reflects Histologically Determined Cortical Bone Volume in Hemodialysis Patients. **Submitted, Osteoporosis International, January 2009.**

Abstracts and Presentations at National/International Meetings

1. Werner E, MALLUCHE HH and Ritz E: Intestinal absorption of Ca in incipient and advanced renal failure. *Europ. J Clin. Invest* 7: p. 421, 1977.
2. MALLUCHE HH, Ritz E and Werner E: The effect of Vitamin D sterols on bone histology in incipient renal failure. *Europ J Clin Invest* 7: p. 251, 1977.
3. MALLUCHE HH, Goldstein DA and Massry SG: Bone disease in nephrotic syndrome without renal failure. *Clin Res* 26: p. 129A, 1978.
4. MALLUCHE HH, Meyer-Sabellek W, Singer FR and Massry SG: Evidence of a direct effect of thiazide on osteolytic osteolysis: A mechanism for the evaluation of serum calcium during thiazide therapy. *Clin Res* 2: p. 47A, 1979.
5. Healy M, MALLUCHE HH, Goldstein DA and Massry SG: The prophylactic use of 1,25(OH)₂D₃ in moderate renal failure. *Clin Res* 2: p. 62A, 1979.

6. Kimmel, DG, MALLUCHE HH, Meyer WA, Keusch G, Healy M, Ritz E and Massry SG: Effects of long-term infusion of physiological dose of PTH on osteoprogenitor cells of bone. *Min Electrol Metab* 2: p. 237, 1979.
7. MALLUCHE HH, Sherman D, Healy M, Norman AW and Massry SG: Skeletal effects of long-term infusion of physiologic doses of 1-34 parathyroid hormone (PTH) on bone. *Clin Res* 28: p. 81A, 1980.
8. Kimmel, D, Healy M, Massry SG and MALLUCHE HH: Bone cell proliferation during chronic infusion of parathyroid hormone. *Clin Res* 28: p. 81A, 1980.
9. MALLUCHE HH, Sherman D, Goldstein DA and Massry SG: Role of parathyroid hormone (PTH) in bone mineralization in *Hormonal Control of Calcium Metabolism* edited by Cohn, DJ, Talmage, RV, Matthews JL, Amsterdam, Excerpta Medical, p. 477, 1981.
10. MALLUCHE HH, Sherman D, Meyer WA, Keusche G, Healy M, Ritz E, Norman AW and Massry SG: Physiological effects of parathyroid hormone on bone in *Hormonal Control of Calcium Metabolism* edited by Cohn, DJ, Talmage, RV, Matthews JL, Amsterdam, Excerpta Medical, p. 409, 1981.
11. MALLUCHE HH, Goldstein DA and Massry SG: Effect of 1,25(OH)₂D₃ on activity of osteoblast, osteoclasts and bone remodeling units in patients with renal osteodystrophy. *Clin. Res.* 29: p. 96A, 1981.
12. MALLUCHE HH, Sherman D, Healy M, Norman AW and Massry SG: Steady state effects of physiologic concentrations of PTH on bone. *Clin. Res.* 29: p. 96A, 1981.
13. MALLUCHE HH, Goldstein DA and Massry SG: The value of 1,25 hydroxyvitamin D₃ in the management of uremic osteodystrophy. *Proceedings II International Symposium: Bone, Structure, Function and Disease, Adelaide, Australia*, p. 8, 1981.
14. MALLUCHE HH, Goldstein DA, Akmal, M and Massry SG: Role of parathyroid hormone in renal osteodystrophy. *VIII International Congress of Nephrology, Athens*, 1981.
15. MALLUCHE HH, Akmal, M, Meyer E, Norman A, Massry SG and Friedler RM: Parathyroid hormone is needed for the positive effect of 1,25(OH)₂ Vit D on bone formation and mineralization in uremia *Calcified Tissue Int Suppl. I*: p. 34, 1982.
16. MALLUCHE HH, Akmal M, Norman A, Massry SG and Friedler RM: 1,25(OH)₂ Vitamin D increases bone formation and mineralization in uremic dogs. *Clin. Res.* 30: p. 744A, 1982.
17. Faugere M-C, MALLUCHE HH, Okamoto, S and DeLuca, HF: Protective effect of 1,25(OH)₂ Vitamin D against bone loss in oophorectomized rats. *Clin. Res.* 30: p. 741A, 1982.
18. MALLUCHE HH, Goldstein DA and Massry SG: 1,25(OH)₂ Vitamin D modulates bone cell number and activity in uremia *Clin. Res.* 30: p. 754A, 1982.
19. MALLUCHE HH, Faugere M-C, Fanti P and Price PA: Serum levels of bone tGla-protein predict underlying bone histology in dialyzed patients. *Kidney Int* 23: p. 105, 1982.
20. Abreo K, Faugere M-C, Smith A, Yokel R, Julian BA, Kluge, R, Friedler RM and MALLUCHE HH: Prevalence and etiology of aluminum intoxication in non-dialyzed and dialyzed patients with renal failure. *Kidney Int* 23: p. 141, 1982.
21. Faugere M-C and MALLUCHE HH: Does bone aluminum intoxication cause resistance to Vitamin D therapy? *Kidney Int* 23: p. 99, 1982.
22. Wyatt RJ, Julian BA, Scott EC, Block, FJ Holland, NH and MALLUCHE HH: Evolution of progressive disease in IgA nephropathy. *Kidney Int* 23: p. 141, 1982.
23. MALLUCHE HH, Faugere M-C and Dorr LD: Systemic changes in bone structure and bone formation in patients with osteoarthritis. *Orthopedic Trans.* 7: p. 299-300, 1983.
24. Faugere M-C, Dorr LD and MALLUCHE HH: Static and dynamic bone histology in primary and revision total knee arthroplasty. *Orthopedic Trans.* 7: p. 300-301, 1983.
25. Faugere M-C, MALLUCHE HH, Okamoto S and DeLuca HF: 1,25(OH)₂D₃ reverses bone loss due to oophorectomy. *Calcif Tissue Int Supp.* 35: p. A10, 1983.

26. MALLUCHE HH, Faugere M–C, Fanti P and Price PA: Bone Gla–protein – A biochemical index of bone formation and mineralization in uremic patients. *Calcif Tissue Int Suppl.* 35: p. 38A, 1983.
27. MALLUCHE HH, Akmal M, Meyer E, Norman A, Massry SG and Friedler RM: 1,25(OH)₂ Vitamin D increases bone formation and mineralization in uremic dogs – An effect dependent upon presence of parathyroid hormone. *Clin. Res.* 31: p. 435A, 1983.
28. MALLUCHE HH, Faugere M–C, Fanti P and Price PA: Bone Gla–protein – A marker for osteoblastic activity. *Clin. Res.* 31: p. 391A, 1983.
29. Faugere M–C, MALLUCHE HH, Okamoto S, DeLuca HF: Protective effect of 1,25(OH)₂ Vitamin D against bone loss in oophorectomized rats. *Clin. Res.* 31: p. 385A, 1983.
30. MALLUCHE HH, Faugere MC, Abreo K, Smith A and Friedler RM: Bone aluminum intoxication in renal failure – etiology, prevalence and effects on Vitamin D therapy. *Clin. Res.* 31: p. 435A, 1983.
31. MALLUCHE HH, Faugere MC, Fanti P and Price PA: Serum levels of bone Gla–protein reflect bone formation and mineralization in dialyzed patients. *Calcif Tissue Int* 35: p. 757A, 1983.
32. MALLUCHE HH, Faugere MC, Abreo K, Smith A and Friedler RM: Aluminum intoxication of bone – etiology and prevalence in renal patients on or before dialysis. *Calcif Tissue Int* 35: p. 672A, 1983.
33. Faugere MC and MALLUCHE HH: Optimal size of bone samples for quantitative and qualitative histology. *Calcif Tissue Int* 35: p. 669A, 1983.
34. Faugere MC and MALLUCHE HH: Does endogenous calcitonin (CT) protect against osteitis fibrosa (OF) in renal failure? *Clin. Res.* 31: p. 738A, 1983.
35. MALLUCHE HH, Smith AJ, Abreo K and Faugere MC: Reversal of bone aluminum accumulation of (BAA) in dialyzed patients treated with desferrioxamine (DFO). *Clin. Res.* 31: p. 750A, 1983.
36. Smith AJ, Faugere MC, Abreo K and MALLUCHE HH: Single desferrioxamine (DFO) infusion (DFO Test) for diagnosis of bone aluminum accumulation of (BAA) in patients with renal failure. *Clin. Res.* 31: p. 751A, 1983.
37. Faugere MC, Ritz E and MALLUCHE HH: Does endogenous calcitonin (CT) protect against osteitis fibrosa (OF) in renal failure? *Kidney Int* 25: p. 142, 1984.
38. Faugere MC and MALLUCHE HH: Endogenous calcitonin is not a long–term modulator of effects of parathyroid hormone on bone. *Physiologist* 27: p. 253, 1984.
39. MALLUCHE HH, Okamoto, S, DeLuca, HF and Faugere MC: Bone loss of estrogen deficiency results from osteoblastic dysfunction – a defect reversed by 1,25(OH)₂ Vit D₃. *Physiologist* 27: p. 253, 1984.
40. Smith AJ, Faugere MC, Abreo K and MALLUCHE HH: The value of single desferrioxamine infusion (DFO Test) for diagnosis of organ aluminum accumulation. *Clin Res* 32: p. 408A, 1984.
41. Faugere MC, Caillens G, Ritz E and MALLUCHE HH: Is there a protective effect of endogenous calcitonin against secondary hyperparathyroidism? *Calcif Tissue Int* 36: p. 476, 1984.
42. Smith AJ, Faugere MC, Abreo K and MALLUCHE HH: The value of single desferrioxamine (DFO) infusion for diagnosis of bone aluminum accumulation (BAA). *Kidney Int* 25: p. 154, 1984.
43. MALLUCHE HH, Smith AJ, Abreo K and Faugere MC: Successful removal of aluminum from bone of dialyzed patients treated with desferrioxamine (DFO). *Kidney Int* 25: p. 188, 1984.
44. Faugere MC and MALLUCHE HH: Does endogenous calcitonin (CT) protect against osteitis fibrosa (OF) in renal failure? *Clin. Res.* 32: p. 394A, 1984.
45. Faugere MC, Reitz R, Endress BP and MALLUCHE HH: Serum parathyroid hormone levels reflect preferentially osteoblastic activity in patients with renal failure. *Clin Res* 32: p. 763A, 1984.
46. Abreo K, Bradac CJ and MALLUCHE HH: Effect of 1,25(OH)₂ Vitamin D on accumulation of aluminum in bone of uremic rats. *Clin Res* 32: p. 769A, 1984.

47. Fanti P, Faugere MC, Price PA and MALLUCHE HH: Plasma levels of bone Gla-protein reflect bone formation and not mineralization or resorption in patients on chronic maintenance dialysis. *Clin Res* 32: p. 769A, 1984.
48. MALLUCHE HH, Abreo K and Faugere MC: Accumulation of aluminum in bone is associated with decreased mineralization and turnover – an effect dependent on the localization of aluminum in bone. *Clin Res* 32: p. 802A, 1984.
49. MALLUCHE HH, Smith AJ, Abreo K and Faugere MC: Reversal of bone aluminum accumulation (BAA) in dialyzed patients treated with desferrioxamine (DFO). *Clin Res* 32: p. 453A, 1984.
50. MALLUCHE HH, Abreo K and Faugere MC: Aluminum decreases turnover and mineralization of bone – an effect dependent on its localization in bone. *Calcif Tissue Int* 36: p. 494, 1985.
51. MALLUCHE HH, Reitz R, Endres D and Faugere M-C: In vivo evidence that parathyroid hormone stimulates preferentially osteoblast rather than osteoclast. *Calcif Tissue Int* 37: p. 477, 1985.
52. MALLUCHE HH, Matthews C, Faugere M-C, Fanti P and Friedler RM: $1,25(\text{OH})_2\text{D}_3$ regulates activity of bone cells and PTH modulates number of bone cells. *Min Electrol Metab* 11: p. 330–331, 1985.
53. Faugere M-C, Abreo K and MALLUCHE HH: Localization of aluminum in bone determines the pathologic effects associated with accumulation of aluminum in bone in hemodialyzed patients. *Kidney Int* 27: p. 114, 1985.
54. MALLUCHE HH, Reitz R, Endres D and Faugere M-C: Serum parathyroid hormone levels predict preferentially osteoblastic activity in patients with renal failure. *Kidney Int* 27: p. 122, 1985.
55. Freundlich M, Strauss J and MALLUCHE HH: Infant formula as a cause of aluminum toxicity in neonatal uremia. *Clin Res* 33: p. 859A, 1985.
56. MALLUCHE HH: $1,25(\text{OH})_2\text{D}_3$ regulates activity of bone cells and parathyroid hormone modulates number of bone cells. *Clin Res* 33: p. 437A, 1985.
57. Fanti P, Smith AJ, Friedler RM, Price PA, Reitz R and MALLUCHE HH: Interrelations between parathyroid hormone, $1,25(\text{OH})_2$ Vitamin D_3 and bone Gla-protein in patients with renal failure. *Kidney Int* 27: p. 137, 1985.
58. Friedler RM, Faugere M-C and MALLUCHE HH: Aluminum causes not only osteomalacia but also osteopenia in hemodialyzed patients. *Kidney Int* 27: p. 161, 1985.
59. Faugere M-C, Bradac CJ and MALLUCHE HH: Bone pathology resulting from bone aluminum accumulation depends upon localization of aluminum in bone. *Clin Res* 33: p. 492A, 1985.
60. MALLUCHE HH, Endres D and Reitz, R: Serum parathyroid hormone levels reflect mainly number of osteoblast rather than number of osteoclast in bone of patients with renal failure. *Clin Res* 33: p. 492A, 1985.
61. Freundlich, M, Faugere M-C, Zilleruelo, G, Strauss, J and MALLUCHE HH: Aluminum accumulation in brain with normal aluminum content in bone resulting from formula feeding of uremic infants. *Clin Res* 33: p. 483A, 1985.
62. Freundlich M, Faugere M-C, Zilleruelo G, Abitbol C, Bradac CJ, Strauss J and MALLUCHE HH: Milk formula causes aluminum toxicity in uremic infants. *Soc Ped Res* 19: p. 376A, 1985.
63. Faugere M-C, Rush M, Friedler RM and MALLUCHE HH: Loss of ovarian function causes bone loss due to an osteoblastic insufficiency in dogs. *Clin Res* 33: p. 849A, 1985.
64. MALLUCHE HH, Faugere M-C, Friedler RM and Fanti P: $1,25(\text{OH})_2\text{D}_3$ increases activity of bone cells in vivo – an effect contrary to the action of PTH on bone. *Sixth Int. Workshop on Vitamin D, Milano, Italy*, 1985.
65. Fanti P, Smith AJ, Friedler RM, Price PA, Reitz, R and MALLUCHE HH: Parathyroid hormone stimulates production of $1,25(\text{OH})_2$ Vit D_3 and bone Gla-protein even in patients without excretory kidney function. *Clin Res* 33:429A, 1985.

66. Cooper K, Schnall S, Duffy T, Solomon L, Hendler E, Ellison A and MALLUCHE HH: Anemia in hemodialysis patients: role of aluminum and response to deferoxamine. *Clin Res* 33:480A, 1985.
67. Faugere M-C, Smith AJ and MALLUCHE HH: Aluminum accumulation in bone causes bone loss in uremic patients. *Clin Res* 33: p. 429A, 1985.
68. MALLUCHE HH, Reitz R, Endres D and Faugere M-C: In vivo evidence that parathyroid hormone stimulates preferentially osteoblast rather than osteoclast. *J Bone Min. Res* 1: p. 134, 1986.
69. Cooper K, Lang R, Ellison A, Hendler E, Faugere M-C and MALLUCHE HH: Aluminum related bone disease: high prevalence despite low dialysate aluminum *J Bone Min Res* 1: p. 92, 1986.
70. Faugere M-C, Matthews C, Friedler RM and MALLUCHE HH: Effects of parathyroid hormone and $1,25(\text{OH})_2\text{D}_3$ on accumulation of aluminum in bone in dogs with renal failure. EDTA, Budapest, Hungary, 1986.
71. Faugere M-C, Arnala IO, Ritz E and MALLUCHE HH: Aluminum causes not only osteomalacia but also osteopenia in hemodialyzed patients. EDTA, Budapest, Hungary, 1986.
72. Faugere M-C, Rush M, Friedler RM and MALLUCHE HH: Loss of ovarian function causes bone loss due to an osteoblastic insufficiency in dogs. *Clin. Res.* 34: p. 544A, 1986.
73. Faugere M-C, Matthews C, Friedler RM and MALLUCHE HH: Effects of parathyroid hormone and $1,25(\text{OH})_2\text{D}_3$ on accumulation of aluminum in bone in dogs with renal failure. *Kidney Int* 29: p. 213, 1986.
74. MALLUCHE HH, Matthews C, Faugere M-C, Fanti P and Friedler RM: $1,25(\text{OH})_2$ Vit D_3 maintains activity of bone cells and PTH modulates number of bone cells in dogs with moderate renal failure. *Kidney Int* 29: p. 165, 1986.
75. Abreo K and MALLUCHE HH: Effect of $1,25(\text{OH})_2\text{D}_3$ and parathyroidectomy on the uptake of aluminum in bone in rats with renal insufficiency. *Clin Res* 34: p. 544A, 1986.
76. Faugere M-C, Friedler RM, Rush M and MALLUCHE HH: Osteoblastic insufficiency is responsible for maintenance of osteopenia after loss of ovarian function. *Int. Conf on Calcium Regulating Hormones*, Nice, France, 1986.
77. MALLUCHE HH, Matthews C, Faugere M-C, Fanti P and Friedler RM: $1,25(\text{OH})_2$ Vit D_3 maintains activity of bone cells and parathyroid hormone modulates number of bone cells in dogs with renal failure. *Int. Conf on Calcium Regulating Hormones*, Nice, France, 1986.
78. Fanti P, Faugere M-C, Smith AJ and MALLUCHE HH: Removal of aluminum (Al) is associated with increased production of $1,25(\text{OH})_2$ Vit D_3 in dialysis patients. *Kidney Int* 31: p. 346, 1987.
79. Smith AJ, Faugere M-C, Fanti P and MALLUCHE HH: Trade in and trade off of deferoxamine (DFO) in therapy in hemodialyzed patients. *Kidney Int* 31: p. 246, 1987.
80. MALLUCHE HH, Fanti P, Friedler RM and Faugere M-C: Decreased activity of bone cells contributes to the pathogenesis of early renal osteodystrophy – an abnormality reversed by $1,25(\text{OH})_2\text{D}$ *Kidney Int* 31: p. 353, 1987.
81. Matthews C, Friedler RM and MALLUCHE HH: Deficiency in parathyroid hormone (PTH) enhances brain aluminum and $1,25(\text{OH})_2$ VitD administration mitigates bone aluminum uptake in dogs with renal failure and long-term aluminum administration. *Kidney Int* 31: p. 354, 1987.
82. MALLUCHE HH, Matthews C, Faugere M-C, Fanti P, Endres DB and Friedler RM: $1,25(\text{OH})_2\text{D}$ maintains bone cell activity and parathyroid hormone modulates bone cell number in experimental dogs. *Transactions of the 33rd Annual Meeting, Orthopedic Research Society*, Vol. 12: p. 286, 1987.
83. Faugere M-C, Friedler RM and MALLUCHE HH: Osteoblastic insufficiency is responsible for maintenance of osteopenia after loss of ovarian function. *Transactions of the 33rd Annual Meeting, Orthopedic Research Society*, Vol. 12: p. 354, 1987.
84. MALLUCHE HH, Faugere M-C and Friedler RM: An osteoblastic defect is responsible for maintenance of bone loss after ovariectomy in dogs. *Bone, Structure, Function and Disease Symposium*, Australia, 1987.

85. MALLUCHE HH, Faugere M-C, Friedler RM and Fanti P: 1,25(OH)₂D reverses bone loss but suppresses bone remodeling in beagle dogs with cessation of ovarian function. Bone, Structure, Function and Disease Symposium, Australia, 1987.
86. Abreo K and MALLUCHE HH: 1,25(OH)₂D₃ and parathyroidectomy on the uptake of aluminum in bone. Clin Res 35, No. 1: p. 31A, 1987.
87. Faugere M-C, Friedler RM, Fanti P and MALLUCHE HH: 1,25(OH)₂D₃ reverses bone loss associated with cessation of ovarian function in experimental dogs. Clin Res 35, No. 3: p. 502A, 1987.
88. MALLUCHE HH: Deficiency in parathyroid hormone enhances brain aluminum and 1,25(OH)₂ Vit D administration mitigates bone aluminum uptake in dogs with renal failure and long-term aluminum administration. Clin Res 35, No. 3: p. 510A, 1987.
89. Fanti P, Faugere M-C, Smith AJ and MALLUCHE HH: Aluminum removal in dialysis patients results in higher circulating levels of 1,25(OH)₂ Vit D. Clin. Res. 35, No. 3: p. 546A, 1987.
90. Faugere M-C, Friedler RM, Fanti P and MALLUCHE HH: The effects of 1,25(OH)₂ Vit D₃ on bone loss associated with cessation of ovarian function in experimental dogs. J Bone Min Res 2: p. 476, 1987.
91. Fanti P, Faugere M-C, Smith AJ and MALLUCHE HH: Removal of aluminum is associated with increased production of 1,25 Vit D in patients with end stage renal failure. J Bone Min Res 2: p. 452, 1987.
92. Smith AJ, MALLUCHE HH, Faugere M-C and Fanti P: Trade in and trade off of deferoxamine (DFO) therapy in hemodialyzed patients. Xth Int. Cong. of Nephrology, London: p. 175, 1987.
93. Fanti P, Faugere M-C, Smith AJ and MALLUCHE HH: Increased blood levels of 1,25 Vit D after aluminum removal in hemodialyzed patients. Xth Int. Cong. of Nephrology, London: p. 423, 1987.
94. Faugere M-C, Friedler RM, Fanti P and MALLUCHE HH: The effects of 1,25(OH)₂D₃ on bone loss associated with cessation of ovarian function in experimental dogs. International Symposium on Osteoporosis, Denmark, Abstract 302, 1987.
95. Faugere M-C, Friedler RM, Fanti P and MALLUCHE HH: The Effects of 1,25(OH)₂D₃ on bone loss associated with cessation of ovarian function in experimental dogs. XX European Symposium on Calcified Tissues, Sirmione, Italy, 1987.
96. MALLUCHE HH, Faugere M-C and Friedler RM: The osteoblastic defect is responsible for maintenance of bone loss after ovariectomy in dogs. XX European Symposium on Calcified Tissues, Sirmione, Italy, 1987.
97. Fanti P, Faugere M-C, Smith A and MALLUCHE HH: Increased blood levels of 1,25 Vit D after aluminum removal in hemodialyzed patients. XXIV Congress of the European Dialysis and Transplantation Association, Berlin, 1987.
98. MALLUCHE HH, Faugere M-C, Friedler RM and Fanti P: Can 1.25 Vit D reverse the bone loss associated with cessation of ovarian function. Transactions of the 34th Annual Meeting Orthopedic Research Society, Volume 13: p. 479, 1988.
99. Dorr LD, Faugere M-C, Bogner B, Mackel AM and MALLUCHE HH: Histologic validation of a new X-ray classification of hip changes in patients with osteoarthritis requiring total hip replacement. Transactions of the 34th Annual meeting Orthopedic Research Society, Volume 13: p. 349, 1988.
100. Fanti P, Friedler RM and MALLUCHE HH: In vivo evidence of extrarenal C-alpha-hydroxylase activity and its immediate response to PTH. Kidney Int 33: p. 338, 1988.
101. Baker LRI, Abrams SML, Roe, CJ, Faugere M-C, Fanti P, Subayti Y and MALLUCHE HH: 1,25 D₃ administration in moderate renal failure. Clin Res 36, No. 3: p. 592A, 1988.
102. Letton RW, Fanti P and MALLUCHE HH: The calcium ionophore A23187 induces a 6-fold increase in the concentration of 1,25(OH)₂D in osteoblast-like cells in vitro. Clin Res 36, No. 3: p. 586A, 1988.
103. Fanti P, Friedler RM and MALLUCHE HH: One minute response of 1,25(OH)₂D to PTH bolus in vivo: evidence for extrarenal sources. Clin Res 36, No. 3: p. 481A, 1988.

104. Baker LRI, Abrams SML, Roe CJ, Faugere M-C, Fanti P, Subayti Y and MALLUCHE HH: 1,25 D₃ administration in moderate renal failure. 7th Workshop on Vitamin D, Rancho Mirage, CA, 1988.
105. Fanti P, Friedler RM and MALLUCHE HH: One minute response of 1,25(OH)₂D to PTH bolus in vivo. 7th Workshop on Vitamin D, Rancho Mirage, CA, 1988.
106. Letton RW, Fanti P and MALLUCHE HH: Several fold increase in concentration of 1,25(OH)₂D due to addition of the calcium ionophore A23187 to osteoblast-like cells in vitro. 7th Workshop on Vitamin D, Rancho Mirage, CA, 1988.
107. Kanis JA, Thavarajah M, Evans D, Norman AW, Horst RL, Uskokovic M, Drezner MK and MALLUCHE HH: Prospects for the modeling of Vitamin D's in man. 7th Workshop on Vitamin D, Rancho Mirage, CA, 1988.
108. Faugere M-C, Friedler RM, Fanti P and MALLUCHE HH: Lack of histologic signs of Vit D deficiency in early development of renal osteodystrophy. *Journal of Bone and Mineral Research* 3, Supplement 1: p. S95, 1988.
109. Fanti P, Friedler RM and MALLUCHE HH: One minute response of 1,25(OH)₂D to PTH: Evidence for extrarenal sources. *Journal of Bone and Mineral Research* 3, Supplement 1: p. S115, 1988.
110. Letton RW, Fanti P and MALLUCHE HH: The calcium ionophore A23187 stimulates 1,25(OH)₂D₃ and suppresses 24,25(OH)₂D₃ in osteoblast-like cells in vitro. *Journal of Bone and Mineral Research* 3, Supplement 1: p. S115, 1988.
111. Fanti P, Letton WR and MALLUCHE HH: 1,25(OH)₂D₃ concentration is increased by the calcium ionophore A23187 in osteoblast-like cells in culture. *Journal of Bone and Mineral Research* 3, Supplement 1: p. S115, 1988.
112. Baker LRI, Abrams SML, Roe CJ, Faugere M-C, Fanti P, Subayti Y and MALLUCHE HH: Bone histomorphometric changes after 1,25 D₃ administration in moderate renal failure. *The Fifth International Congress on Bone Morphometry*, Niigata, Japan, p. 71, 1988.
113. Faugere M-C, Friedler RM, Fanti P and MALLUCHE HH: Lack of histologic signs of Vit D deficiency in the early development of renal osteodystrophy, *Fifth International Congress on Bone Morphometry*, Niigata, Japan, p. 118, 1988.
114. Baker LRI, Abrams SML, Roe CJ, Faugere M-C, Fanti P, Subayti Y and MALLUCHE HH: Bone histomorphometric changes after 1,25 D₃ administration in moderate renal failure. *V International Congress on Nutrition and Metabolism in Renal Disease*, Strasbourg, France, 1988.
115. MALLUCHE HH and Faugere M-C: Diagnosis of Aluminum Bone Disease. *XXV Congress of the European Dialysis and Transplant Association*, Madrid, Spain, 1988.
116. Dunlay RW, Allon M, Fanti P and MALLUCHE HH: The role of Calcitriol (CTR) in prolonged hypocalcemia due to tumor lysis syndrome (TLS). *Kidney Int* 35: p. 215, 1988.
117. Baker LRI, Abrams SML, Roe, CJ, Faugere M-C, Fanti P, Subayti Y and MALLUCHE HH: Use of 1,25D₃ in patients with moderate renal failure. *Kidney Int* 35: p. 220, 1988.
118. Faugere M-C, Friedler RM, Fanti P, MALLUCHE HH: Lack of histologic signs of Vit D deficiency in the early development of renal osteodystrophy *Kidney Int.* 35: p. 377, 1988.
119. MALLUCHE HH, Dorr LR, Bognar B, Faugere M-C: Osteopenia in 97 patients with osteoarthritis. *Orthopedic Research Society*, Feb., 1989.
120. Faugere M-C, Friedler RM, Fanti P, MALLUCHE HH: Incipient histological and biochemical derangement's of renal osteodystrophy *Clin Res* 37, No. 2: p. 570A, 1989.
121. MALLUCHE HH, Faugere M-C, Fanti P, Abrams SML, Baker LRI: Calcitriol administration in moderate renal failure. *Calcium '89: Prague, Czechoslovakia, 1989 2nd International Symposium on Preventive and Therapeutic Use of Calcium, Vitamin D and Other Calcitropic Drugs*.
122. MALLUCHE HH, Faugere MC, Friedler RM, Fanti P: Development of bone loss after cessation of ovarian function and its reversal with 1,25(OH)₂D₃. *Steenbock Symposium on Osteoporosis*, University of Wisconsin-Madison, 1989.

123. Faugere M–C, Friedler RM, Fanti P, MALLUCHE HH: Induction and maintenance of bone loss after cessation of ovarian function. *J Bone and Min Res* 4: p. S176, 1989.
124. Fanti P, Friedler RM, MALLUCHE HH: In vivo evidence that parathyroid hormone induces a rapid rise of 1,25(OH)₂D₃ from low blood levels. *J Bone and Min Res* 4: p. S388, 1989.
125. Subayti Y, Fanti P, MALLUCHE HH: Increased circulating levels of 1,25(OH)₂D and upregulation of the intestinal of 1,25(OH)₂D receptor early after ovariectomy in rats. *J Bone and Min Res* 4: p. S393, 1989.
126. MALLUCHE HH, Slatopolsky, E, Faugere M–C: The deferoxamine infusion test (DFO test): a multicenter study. *Kidney Int* 37: p. 309, 1990.
127. Fanti P, Friedler RM, MALLUCHE HH: Renal and extrarenal sources are involved in the rapid regulation of serum 1,25(OH)₂D₃ (1.25D) in thyroparathyroidectomized (PTX) dogs. *Kidney Int* 37: p. 466, 1990.
128. Fanti P, Friedler RM, MALLUCHE HH: Parathyroid hormone stimulate renal and extrarenal sources to induce a rapid rise of 1,25(OH)₂D levels in parathyroidectomized dogs. *International Congress of Nephrology, Tokyo, Japan, 1990.*
129. MALLUCHE HH, Slatopolsky E, Faugere M–C: Can aluminum bone disease be diagnosed by noninvasive tests? *International Congress of Nephrology, Tokyo, Japan, 1990.*
130. Kimmel P, Watkins D, Bogнар B, Langman C, MALLUCHE HH: Zinc depletion and renal osteodystrophy in the rat. *International Congress of Nephrology, Tokyo, Japan, July, 1990.*
131. Colombo G, Fanti P, Yao C, MALLUCHE HH: Purification and complete amino acid sequence of osteocalcin from canine bone. *Proceedings: Seventh International Symposium on Calcium Binding Proteins in Health and Disease, Banff, Canada, March 1990.*
132. John J, MALLUCHE HH, Kerschbaumer W: Wirbelkorperkompressionsfraktur bei Aluminiuminduzierter Osteodystrophie nach Langjahriger Antazida–Medikation. *Proceedings of the Fifth Annual Meeting of Deutsche Gesellschaft fur Osteologie, 1990.*
133. Dorr LD, Gruen, TAW, Faugere M–C, MALLUCHE HH: Influence of bone on failure of THR. *18th World Congress of the Societe Internationale de Chirurgie Orthopedique et de Traumatologie, Montreal, 1990.*
134. Kurz P, Bogнар B, Roth P, Werner E, Vlachoјannis, J, Grutzmacher, P, Faugere M–C, MALLUCHE HH: Relationship between bone turnover and plasma calcium clearance (CACL) in patients with uremic bone disease. *Renal Bone Disease, PTH and Vitamin D Symposium, 1990.*
135. Kurz P, Bogнар B, Roth P, Werner E, Faugere M–C, MALLUCHE HH, Vlachoјannis, J, Grutzmacher, P: Beziehung zwischen Knochen turnover und der Plasmacalciumclearance in Patienten mit Uramischer Osteodystrophie. *21 Kongress der Gesellschaft fur Nephrology, Badgastein, September 1990.*
136. Colombo G, Fanti P, Yao C and MALLUCHE HH: Purification and complete amino acid sequence of bone GLA protein (BGP) from canine bone. *J Bone Min Res* 5: p. S232, 1990.
137. Faugere M–C, Friedler RM, Fanti P, MALLUCHE HH: Elevation of parathyroid hormone in incipient renal failure: a compensatory mechanism to offset decreased 1,25 Vit D levels. *J Bone Min Res* 5: p. S238, 1990.
138. Fanti P, Mohapatra S, Klein J, Kindy M, Colombo G, MALLUCHE HH: Aluminum (AL) exerts a biphasic effect on bone GLA protein (BGP) in 1,25D stimulated rat osteosarcoma cells (ROS 17/2) in culture. *J Bone Min Res* 5: p. S238, 1990.
139. MALLUCHE HH, Friedler RM, Fanti P, Faugere M–C: Elevated PTH levels are needed for normal serum 1,25D in incipient renal failure. *J Am Soc of Nephrol*, No. 4: p. 587, 1990.
140. Fanti P, Kindy M, Mohapatra, S, Klein J, Colombo G, MALLUCHE HH: Effects of Al on BGP in osteoblastic cells in culture. *J Am Soc of Nephrol* 1, No. 4: p. 570, 1990.
141. Kimmel, P, Bogнар B, Watkins, D, Faugere M–C, Langman, C, MALLUCHE HH: Zinc depletion and renal osteodystrophy in the rat. *23rd Annual Meeting, J Am Soc of Nephrol*, No.4, 1990.

142. MALLUCHE HH, Friedler RM, Fanti P, Faugere M-C: Secondary hyperparathyroidism – A compensatory phenomenon to overcome low 1,25Vit D levels in incipient renal failure. *Calc Tiss.* 48: p. A86, 1991.
143. Bognar B, Faugere M-C, MALLUCHE HH: Cyclic administration of 1,25(OH)₂D₂ and 1,25(OH)₂-24EPI-D₂ prevents bone loss in ovariectomized rats. *J Bone & Min Res* 6: p. S239, 1991.
144. Faugere M-C, Bognar B, Friedler RM and MALLUCHE HH: 1,25R,26(OH)₃-22 ene D₃ (RO 23-8525) reverses bone loss associated with cessation of ovarian function without suppression of bone turnover in experimental dogs. *J Bone Min Res* 6: p. S216, 1991
145. Juvin, R, Allen, SH, Faugere M-C and MALLUCHE HH: Serum tartrate-resistant acid phosphatase reflects histomorphometric parameters of osteoclast in dialyzed patients. *J Bone Min Res* 6: p. S152, 1991
146. Klein J, Fanti P, Franz, HE and MALLUCHE HH: Effect of parathyroid hormone on protein kinase C activity in primary rat osteoblast-like cells. *Kongress der Gesellschaft für Nephrologie.* Heidelberg, Germany, September, 1991.
147. MALLUCHE HH, Juvin R, Allen SH and Faugere M-C: Serum tartrate-resistant acid phosphatase reflects osteoclastic resorption better than PTH in dialyzed patients. *J Am Soc of Nephrol* 2(3): p. 337, 1991.
148. MALLUCHE HH, Juvin R, Allen SH and Faugere M-C: Magnesium administration prevents the thiazide-induced increase in osteocyte number in normal dogs. *J Am Soc of Nephrol* 2(3): p. 620, 1991.
149. Metsger DS, Arnala I, Faugere M-C and MALLUCHE HH: Histomorphometric analysis of tricalcic phosphate ceramic implanted into turkeys. *Proceedings: Fourth World Biomaterial Congress, Berlin, Germany, 1992.*
150. Arnala I, Tarvainen R, Nevalainen T., Alhava E, Faugere M-C, MALLUCHE HH: Clodronate does not affect bone resorption or bone turnover in dietary-induced hyperparathyroidism in beagle dogs. *J Bone Miner Res* 7: (Suppl. 1): p. 289, 1992.
151. Monier-Faugere M-C, Friedler RM, Bauss F, MALLUCHE HH: A new bisphosphonate, BM21.0955, prevents bone loss occurring after cessation of ovarian function in experimental dogs. *J Bone Miner Res* 7 (Suppl. 1): p. 277, 1992.
152. Fanti P, Colombo G, Yao C, Brown S, Vernon MW, MALLUCHE HH: Development and characterization of a radioimmunoassay (RIA) for dog osteocalcin. *J. Bone Miner Res* 7 (Suppl. 1): p. 266, 1992.
153. Kimmel PL, Bognar B, Watkins D, Faugere M-C, Langman C, MALLUCHE HH: Zinc depletion limits hyperparathyroid renal osteodystrophy in rats. *J Am Soc of Nephrol* 3(3): p. 674 1992.
154. Kurz P, Tsobanelis T, Roth P, Werner E, Bruns M, Vlachoianis J, MALLUCHE HH: Differenzierung der renalen Osteopathie mit Hilfe kalziumkinetischer Parameter Osteologie. *Suppl. 1, Band 1: p. 46, 1992.*
155. Thiel G, Briner V, MALLUCHE HH: Verlauf der Renalen Osteopathie nach erfolgreicher Nierentransplantation. *24 Kongress der Gesellschaft für Nephrologie, Hamburg, Germany, 1993.*
156. Costa M, Faugere M-C, MALLUCHE HH: Persistence of aluminum bone disease despite substitution of aluminum containing phosphate binders by calcium salts in patients on chronic dialysis. *J Am Soc of Nephrol* 4(3): p. 694, 1993.
157. Faugere M-C, Friedler, RM, MALLUCHE HH: Efficacy and limitations of pulse I.V and pulse oral 1,25 Vit D therapy on bone disease in patients on chronic dialysis. *J Am Soc of Nephrol* 4(3): p. 695, 1993.
158. Kurz P, Tsobanelis T, Roth P, Werner E, Faugere M-C, Schoeppe W., Vlachoianis J, MALLUCHE HH: Calcium turnover is lower in patients on continuous ambulatory peritoneal dialysis (CAPD) than in hemodialyzed patients (HD) despite similar PTH levels. *J Am Soc of Nephrol* 4(3): p. 410, 1993.
159. MALLUCHE HH, Faugere M-C, Hruska K, Salusky I, Sawaya P: Bone biopsies in patients with renal failure: Why, When and How. *Short course, J Am Soc of Nephrol* 4(3): p. 11, 1993.

160. MALLUCHE HH: Skeletal lead as a potential contributing factor to the development of bone diseases. NIEHS Lead Bone Metabolism Workshop, Research Triangle Park, NC, 1993.
161. Koszewski NJ, Lapuz MH, Russell J and MALLUCHE HH: Footprint analysis of the Vitamin D receptor binding to the human osteocalcin response element: Implications for heterodimer interactions. Proceedings of the Ninth Workshop on Vitamin D, 1994.
162. Lapuz MH, Koszewski NJ, Faugere MC, Jueppner H, MALLUCHE HH: Demonstration of human parathyroid hormone receptor messenger ribonucleic acid in osteoblasts, lining cells and osteocytes of plastic-embedded bone biopsy specimens from uremic patients, *J Bone Miner Res* 9: p. S232, 1994.
163. Colombo G, Fanti P, MALLUCHE HH: Interaction of osteocalcin with bone cells, *J. Bone Miner. Res.* 9: p. S245, 1994.
164. Koszewski NJ, Lapuz MH, Russell J, MALLUCHE HH: Vitamin D receptor interactions with positive and negative DNA response elements: An interface footprint comparison, *J. Bone Miner. Res.* 9: p. S290, 1994.
165. Fanti P, Combs TR, Kindy MS, Colombo G, MALLUCHE HH: Aluminum affects parathyroid hormone-induced production of osteocalcin without altering expression of osteocalcin messenger ribonucleic acid. *J Bone Miner Res* 9: p. S226, 1994.
166. Geng ZP, Faugere MC, Qi QL, MALLUCHE HH: Predictive value of serum osteocalcin for bone turnover in patients with osteoporosis. *J Bone Miner Res* 9: p. S402, 1994.
167. Doers T, Pienkowski D, Faugere MC, MALLUCHE HH. Calcitonin reduces bone mineral density and torsional mechanical properties of canine tibiae. *J Am Soc of Nephrol* 9: p. S268, 1994.
168. Qi QL, Faugere MC, Geng AP, MALLUCHE HH: Sensitivity and specificity of serum levels of intact parathyroid hormone in predicting bone turnover in renal osteodystrophy. *J Bone Miner Res* 9: p. S228, 1994.
169. Kurz P, Monier-Faugere MC, Bogner B, Werner E, Roth P, Vlachoianis J, MALLUCHE HH: Calcium kinetics studies in patients with renal osteodystrophy. Proceedings 31st Congress of the EDTA European Renal Association, Vienna, Austria, 1994.
170. Briner V, Thiel G., Faugere MC, Landsmann J, MALLUCHE HH. Prevention of osteopenia but persistence of renal bone disease after kidney transplantation. *J Am Soc of Nephrol* 5(3): p. 996, 1994.
171. Faugere MC, Qi QL, Geng ZP, MALLUCHE HH. What serum levels of parathyroid hormone discriminate between high vs. normal or low bone turnover in dialyzed patients? *J Am Soc of Nephrol* 5(3): p. 878, 1994.
172. Sawaya B, Qi QL, Faugere MC, MALLUCHE HH. High bone turnover (HBT) without increase in serum parathyroid hormone (PTH) in rats with mild chronic renal failure (MCRF). *J Am Soc of Nephrol* 5(3): p. 888, 1994.
173. Fanti P, Combs TR, Kindy MS, Colombo G, MALLUCHE HH. The effect of aluminum (Al) on the parathyroid hormone (PTH)-stimulated production of osteocalcin (OC) is not mediated by altered expression of OC. *J Am Soc of Nephrol* 5(3): p. 890, 1994.
174. Walker J, Faugere MC, Arnala I, MALLUCHE HH. Bone histomorphometry in children with myelomeningocele and cerebral palsy – preliminary results. *Dev. Med. Child Neurol* 36 (9) Suppl 70; 3, 1994.
175. Doers T, Pienkowski, Faugere MC, MALLUCHE HH. Calcitonin reduces bone mineral density and load bearing mechanical properties of canine bones, *Transactions of the 41st Orthopedic Research Society.* p.156, 1995.
176. Faugere MC, Briner V, Thiel G, MALLUCHE HH. Prevention of osteopenia but persistence of renal bone disease two years after kidney transplantation. *J Bone Miner Res.* 10(Suppl.1): p. S512, 1995.
177. Qi Q, Faugere MC, Geng Z, MALLUCHE HH. Calcitonin prevents the early bone loss after cessation of ovarian function but induces osteoblastic insufficiency in beagle dogs. *J Bone Miner Res* 10(Suppl.1): p. S354, 1995.

178. Geng Z, Faugere MC, Qi Q, Bauss F, MALLUCHE HH. Ibandronate reverses bone loss after cessation of ovarian function in beagle dogs. *J Bone Miner Res* 10(Suppl. 1): p. S199, 1995.
179. Faugere MC, Geng Z, Qi Q, MALLUCHE HH. Effects of calcitonin on bone loss after cessation of ovarian function in beagle dogs—evidence for an osteoblastic insufficiency. *Transactions of the Orthopedic Research Society*, 1995.
180. Faugere MC, Geng Z, Qi Q, MALLUCHE HH. Serum levels of insulin-like growth factor-1 and its binding protein-3 do not reflect bone formation in patients on chronic maintenance dialysis. *J Am Soc of Nephrol* 6(3): p. 970, 1995.
181. Sawaya, B.P., Koszewski, N., Fanti, P., Qi, Q., Faugere, M.C., MALLUCHE, HH: Evidence for abnormal binding of vitamin D-receptor complex to vitamin D response elements (VDRE) in rats with incipient renal failure. *J Am Soc of Nephrol* 6(3): p. 935, 1995
182. Koszewski, N.J., and MALLUCHE, HH. Interactions of the vitamin D receptor with the murine osteopontin response element. 17th Ann Mtg Am Soc Bone and Mineral Research, *J Bone Miner Res* 10: p. S553, 1995.
183. McCarter, J., Pienkowski, D., Faugere, M-C, MALLUCHE, HH, Kryscio, R. Compatibility of bone mineral densities and mechanical properties of vertebrae and long bones in a canine model. 42nd Annual Meeting, Orthopedic Research Society. 1996
184. Langub, M.D., Loszewski, N.J., Faugere, M.-C., Geng, Z., and MALLUCHE, HH. Intensity of mRNA expression for interleukin-6 receptor in osteoclasts parallels bone resorption in patient with renal osteodystrophy. 18th Ann Mtg Am Soc Bone and Mineral Research, *J Bone Min Res* 11: p. S491, 1996.
185. Geng Z, Faugere M-C, Qi Q, Slatopolsky E, Friedler RM, Kubodera N, MALLUCHE HH. 22-Oxacalcitriol suppresses parathyroid hormone secretion and preserves bone turnover in dogs with renal failure. *J Bone Miner Res* 11(Suppl 1): p. S490, 1996.
186. Langub, M.C., Herman, J.P., MALLUCHE, HH, and Koszewski, N.J. Immunoreactivity for retinoid X receptor isoforms in specific brain sites of the rat. Society for Neuroscience, Washington, D.C., 1996.
187. Qi Q, Faugere M-C, Geng Z, Devane J, MALLUCHE HH. 24-epi-alpha, 25 dihydroxyvitamin D2 reverses bone loss after cessation of ovarian function without inducing low bone turnover in beagle dogs. *J Bone Miner Res* 11(Suppl 1): p. S225, 1996.
188. Fanti, P., M-C. Faugere, Z. Geng, J. Schmidt, D. Cohen, MALLUCHE HH. Systemic administration of genistein partially prevents bone loss in ovariectomized rats via a non estrogen-like mechanism. Second International Symposium, Soybean Association, 1996.
189. Sawaya, B.P., Koszewski, N.J., Langub, M.C., MALLUCHE HH: A retinoid X receptor (RXR) isoform is reduced in the remnant kidney of rats with mild renal failure. *J Am Soc Neph* 7 (9), 1996.
190. Faugere, M.C., Geng, Z., Qi, Q., Slatopolsky, E., Friedler, R.M., Kubodera, N., MALLUCHE, HH: Prevention of secondary hyperparathyroidism without suppression of bone turnover in dogs with renal insufficiency treated with 22-Oxacalcitriol. *J Am Soc Nephrol* 7(9): p. 1790, 1996.
191. Sawaya, B.P., Koszewski, N.J., Qi Q., Langub, M.C., Faugere, M-C, MALLUCHE HH: Defective vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure. *Am Soc Bone Miner Res Annual Meeting*, 1996.
192. Vasconez, H.C., Rodgers, J.B., Fink, B.F., Deluca, P., Faugere, M.C., MALLUCHE HH: Nerve Regeneration Through a “Sliding Epineurial Sheath Tube” Conduit by an End-to-Side Coaptation: Role of Fresh vs. Pre-Degenerated Nerve. 1996 Poster Presentation, 41st Annual Meeting Plastic Surgery Research Council.
193. Faugere, M.C., Qi, Q., Geng, Z., Devane, J., MALLUCHE HH: Correction of bone loss with estrogen deficiency by 24-epi-1 α ,25-dihydroxyvitamin D₂. *Bone* 19 (3, Suppl): p. S140, 1996.
194. Langub, M.C. Jr., Koszewski, N.J., Faugere, M.C., Geng, Z., MALLUCHE, H.H.: Erosion depth is paralleled by expression of mRNA for interleukin-6 receptor in osteoclasts. *Bone* 19 (3, Suppl): p. S148, 1996.

195. Geng, Z., Faugere, M.C., Qi, Q., Slatopolsky, E., Friedler, R.M., Kubodera, N., MALLUCHE, H.H.: Suppression of PTH secretion without concomitant decrease in bone turnover in renal failure. *Bone* 19 (3, Suppl): p. S141, 1996.
196. Vasconez, H., Rodgers, J., Fink, B., Duggirala, S., Deluca, P., Faugere, M., MALLUCHE HH: Rabbit study of novel delivery vehicles for rhBMP. *Bone* 19 (3, Suppl): p. S166, 1996.
197. Pienkowski, D., McCarter, J., Doers, T., Maitra, R., Monier-Faugere, M.C., MALLUCHE HH: Bone mineral density compares and contrasts with the biomechanical measurements of canine bone. *Bone* 19 (3, Suppl): p. S159, 1996.
198. Vasconez, H.C., Rodgers, J.B., Fink, B.F., Deluca P, Faugere, M.C., MALLUCHE HH: A novel delivery vehicle for growth factors in cranial bone surgery, a rabbit study. Poster presentation, 41st Annual Meeting, Plastic Surgery Research Council, St. Louis, MO, June 1996.
199. Rastogi, R., Faugere, M.C., Geng, Z., Bogнар, B., MALLUCHE HH: Cyclosporin does not induce bone loss but enhances mineralization in normal and nephrectomized rats. *J Bone Miner Res* 12 (Suppl 1): p. S402, 1997.
200. Geng, Z., Faugere, M.C., Pienkowski, D., Boskey, A., MALLUCHE HH: Calcitonin alters bone quality in canine bone. *J Bone Miner Res* 12(Suppl 1): p. S238, 1997.
201. Qi, Q., Faugere, M.C., Langub, M.C. Jr., MALLUCHE HH: Validation of quantitative in situ hybridization histochemistry in mineralized bone. *J Bone Miner Res* 12(Suppl 1): p. S410, 1997.
202. Fanti, P., Faugere, M.C., Geng, Z., Schmidt, J, Cohen, D., MALLUCHE HH: Genistein reduces bone loss in ovariectomized rats. *J Bone Miner Res* 12(Suppl 1): p. S477, 1997.
203. Langub, M.C. Jr., Faugere, M.C., Koszewski, N.J., Qi, Q., MALLUCHE HH: Early increase in osteoblastic interleukin-6 mRNA expression in ovariectomized rats. *J Bone Miner Res* 12 (Suppl 1): p. S332, 1997.
204. Langub, C., Herman, J.P., Horst, R.L., Reinhardt, T.A., MALLUCHE, H.H., Kozsewski, N.J.: Localization of 1,25-Dihydroxyvitamin D receptors in the rat hippocampus. *Soc for Neuro* 23: p. 1497, 1997.
205. Langub, C., Sawaya, B.P., Horst, R.L., Reinhardt, T.A., MALLUCHE, H.H., Kozsewski, N.J.: Co-localization of retinoid X receptor alpha and vitamin D receptor in rat parathyroid glands. *J Am Soc Nephrol* 8: p. 576A, 1997.
206. Faugere, M.C., Langub, M.C., Qi, Q., Geng, Z., MALLUCHE, H.H., Parathyroid hormone receptor mRNA expression in bone cells parallels bone turnover in dialyzed patients. *J Am Soc Nephrol* 8: p. 551A, 1997.
207. Sawaya, B.P., Langub, M.C., Kozsewski, N.J., MALLUCHE, H.H.: Retinoid X receptor alpha (RXR α) mRNA and protein are reduced in parathyroid glands (PTG) of rats with mild renal failure. *J Am Soc Nephrol* 8: p. 580A, 1997.
208. MALLUCHE, H.H., Langub, M.C. Jr., Monier-Faugere, M.C.: Pathogenesis and histology of renal osteodystrophy. *Osteoporosis Int* 7(Suppl 20): p. 7, 1997.
209. Geng, Z.P., Faugere, M-C, MALLUCHE, H.H.: Calcitonin prevents bone loss but decreases osteoblastic activity in ovariectomized beagle dogs. 5th National Osteoporosis Conference, Anhui, P.R. China, 1997.
210. Geng, Z.P., Fanti, P., Faugere, M-C, Cohen, D., MALLUCHE, H.H.: Moderately high consumption of ethanol suppresses histologic parameters of bone resorption in ovariectomized but not in sexually intact adult female rats. 82nd Fragrance Mountain Science Conference, Beijing, P.R. China, 1997.
211. Faugere, M.C., Langub, M.C., Qi, Q., MALLUCHE, H.H.: Parathyroid hormone receptor mRNA expression in bone cells parallels bone turnover in dialyzed patients. *J. Am Soc Nephrol* 9: p. 544A, 1998.

212. Langub, M.C., Faugere, M.C., Qi, Q., MALLUCHE, H.H.: Positive feed-forward regulation of PTH/PTHrP receptors in dialyzed patients with high turnover bone disease. *J Am Soc Nephrol* 9: p. 547A, 1998.
213. Rastogi, S., Geng, Z., Faugere, M.C., MALLUCHE, H.H.: Tacrolimus induces bone loss by increasing bone turnover and bone resorption. *J Am Soc Nephrol* 9: p. 714A, 1998.
214. Chu, P., Faugere, M.C., MALLUCHE, H.H.: Bone loss in renal failure due to bone lead accumulation at low serum levels. *J Am Soc Nephrol* 9: p. 68A, 1998.
215. Pienkowski, D., Doers, T., Maitra, R., Faugere, M.C., MALLUCHE, H.H.: BMD predicts the maximum compressive load-bearing properties of vertebrae, but not the maximum torque-bearing properties of long bones. *Bone* 23(5): p. S437, 1998.
216. Langub, M.C., Qi, Q., Faugere, M.C., MALLUCHE, H.H.: High serum PTH levels do not downregulate PTH/PTHrP receptors in osteoblasts in dialyzed patients. *Bone* 23(5): p. S576, 1998.
217. Puleo, D.A., Langub, M.C., Koszewski, N.J., Faugere, M., MALLUCHE, H.H.: Less inhibitory and antiproliferative effects of 24-epi-D₂ than 1,25(OH)₂D₃ on bone marrow stromal cells of aged rats. *Bone* 23(5): p. S418, 1998.
218. Zhao, G., Faugere, M.C., MALLUCHE, H.H., Wang, J., Nakayama, T., Pike, J., Fagin, J., Clemens, T.: Osteoblast-specific overexpression of IGF-1 in transgenic mice increases cancellous bone volume. *Bone* 23(5): p. S172, 1998.
219. Langub, M.C., Faugere, M.C., MALLUCHE, H.H.: Presence of mRNA for PTH receptors in human osteoclasts with evidence for translation to its protein in pathologic but not normal condition. *J Bone Miner Res* 14(Suppl 1): p. F154, 1999.
220. Faugere, M.C., Qi, Q., Mawad, H., MALLUCHE, H.H.: Bone disease after kidney transplantation: high prevalence of low bone turnover and delayed mineralization. *J Bone Miner Res* 14 (Suppl 1): p. F423, 1999.
221. Faugere, M.C., Mawad, H., Friedler, R.M., MALLUCHE, H.H.: High prevalence of low bone turnover and delayed mineralization in patients after kidney transplantation. *J Am Soc Nephrol* 10: p. 756A 1999.
222. Sawaya, B.P., Kulubya, P., Babalakin, O., MALLUCHE, H.H., Sloan, D.: Long-term outcome of subtotal parathyroidectomy (PTX) in ESRD patients: evidence against the need for autotransplantation (ATX). *J Am Soc Nephrol* 10: p. 624A, 1999.
223. Fanti, P., Sawaya, B.P., Ratanapanichkich, P., MALLUCHE, H.H.: African-Americans with ESRD have higher parathyroid hormone (PTH) Levels at the Initiation of renal replacement therapy (RRT). *J Am Soc Nephrol* 10: p. 618A, 1999.
224. Langub, M.C., Faugere, M.C., Qi, Q., MALLUCHE, H.H.: Relationship of PTH/PTHrP receptor expression with erosion depth in individuals with elevated serum PTH levels. VII Congress of the International Society of Bone Morphometry, 1999.
225. MALLUCHE, H.H., Geng, Z., Qi, Q., Faugere, M.C.: Comparison between continuous and intermittent therapy with the bisphosphonate ibandronate on bone volume, bone turnover and mineral properties in dogs after cessation of ovarian function. VII Congress of the International Society of Bone Morphometry, 1999.
226. Mawad, H., Faugere, M.C., Qi, Q., Friedler, R.M., MALLUCHE, H.H.: Post-transplant bone disease: Histologic assessment in 57 patients. VII Congress of the International Society of Bone Morphometry, 1999.
227. Geng, Z., Faugere, M.C., Bauss, F., MALLUCHE, H.H.: The bisphosphonate ibandronate increases bone volume and decreases bone resorption and bone turnover in experimental renal failure in rats. VII Congress of the International Society of Bone Morphometry, 1999.
228. Clemens, T., Zhao, G., Faugere, M.C., Langub, C., Wang, J., Nakayama, T., Pike, J., Fagin, J., MALLUCHE, HH: Transgenic approaches for studying IGF action in bone. VII Congress of the International Society of Bone Morphometry, 1999.

- 229 Sawaya, P., Butros, R., Monier-Faugere, M.C., Geng, Z., Fanti, P., MALLUCHE, H.H.: Bone turnover in patients with ESRD and moderately elevated serum parathyroid hormone (PTH): evidence for the usefulness of evaluating the trend in PTH. *J Am Soc Nephrol* 11: p. 582A, 2000.
- 230 Langub, M.C., Reinhardt, T.A., Horst, R.L., MALLUCHE, H.H., Koszewski, N.J.: Demonstration of vitamin D receptor immunoreactivity in osteoclasts of human bone. *J Bone Miner Res* 15: p. S454, 2000.
- 231 Langub, M.C., Tondravi, M., Monier-Faugere, M.C., MALLUCHE, H.H.: Demonstration of osteoprotegerin–ligand expression in normal bone and in patients with increased bone resorption. *J Bone Miner Res* 15: p. S493, 2000.
- 232 Langub, M.C., Tondravi, M., Monier-Faugere, M.C., Malluche, H.H.: Increased osteoprotegerin–ligand expression in bone of patients with renal osteodystrophy. *J Am Soc Nephrol* 11: p. 555A, 2000.
- 233 MALLUCHE, H.H., Mawad, H., Faugere, M.C.: Renal bone disease post-transplantation. Submitted to Transplant Bone Disease Meeting, XVIII International Congress of the Transplantation Society, 2000.
- 234 Zhang, M., Faugere, M., MALLUCHE, H.H., Rosen, C.J., Chersausek, S.V., Clemens, T.L.: Paracrine Overexpression of IGF1BP-4 in Osteoblasts of Transgenic Mice Results in Global Growth Retardation. *J Bone Min Metab* 2001.
- 235 Faugere, M.C., Langub, M.C., MALLUCHE, H.H.: PTH-(7–84) Antagonizes the Effects of PTH-(1–84) on Bone Turnover in Rats. *J Bone Min Metab* 2001.
- 236 Bogner, I., Coco, M., Glicklich, D., Burris, L., Durkin, P., Tellis, V., Greenstein, S., Schenar, R., McDonough, P., Figueroa, K., Faugere, M.C., MALLUCHE, H.H.: Randomized trial of IV pamidronate to ameliorate bone loss in renal transplant recipients. *New York Society of Nephrology*, 2001.
- 237 Alimov, A., Peng, X., MALLUCHE, H.H., Koszewski, N.: Bending Analysis of CDR Binding to Positive and Negative DNA Response Elements. *J Bone Min Metab* 2001.
- 238 Zhang, M., Xuan, S., Bouxsein, M.L., von Stecho, D., Faugere, M., MALLUCHE, H.H., Zhao, G., Rosen, C.J., Efstratiadis, A., Clemens, T.L.: Conditional Mutagenesis of the IGF1 Receptor Gene in Osteoblasts Reduces Cancellous Bone Volume and Increases Turnover. *J Bone Min Metab* 2001.
- 239 Sawaya, B.P., Monier-Faugere, M.C., Butros, R., Geng, Z., Mawad, H., Friedler, R.M., Fanti, P., MALLUCHE, H.H.: Intact parathyroid hormone levels are not predictive of bone turnover in African-American patients with ESRD. *J Am Soc. Nephrol* 2001.
- 240 Faugere MC, Zhang M, Bouxsein ML, MALLUCHE, H.H., Efstratiadis A, Clemens TL: Conditional mutagenesis of the IGF-1 receptor gene in osteoblasts reveals an essential role of IGF-1 in mineralization, IX Congress of International Society of Bone Morphometry, Edinburgh, 2002.
- 241 Alimov, A.P., Langub, M.C., MALLUCHE, H.H., Koszewski, N.J.: Sp1-like binding activity present in parathyroid glands that binds to a region of the parathyroid hormone gene promoter. *J Am Soc Nephrol* 13: p. 193A, 2002.
- 242 Rowan A, MALLUCHE, H.H., Langub, MC: Demonstration of Type 1 Parathyroid Hormone Receptor in Cultured Human Osteoclasts. *J Am Soc Nephrol* 13: p. 577A, 2002.
- 243 Coco, M, Glicklich, D, Burris, L, Bogner, I, Tellis, V, Greenstein, S, Schechner, G, Wang, G, Faugere, MC, MALLUCHE, H.H.: Prospective Randomized Trial of IV Pamidronate in Renal Transplant Recipients: 6 and 12 Month Follow-Up. *J Am Soc Nephrol* 13: p. 10A, 2002.
- 244 MALLUCHE HH, Monier-Faugere MC, Wang G, Frazao JM, Charytan C, Coburn JW, Coyne D, Kaplan M, Baker N, McCary LC, Turner SA, Goodman WG. Cinacalcet HCl reduces bone turnover and fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT). *World Congress of Nephrology*, Berlin, 2003.
- 245 Sawaya BP, Monier-Faugere MC, Friedler RF, MALLUCHE HH: Racial Differences in Bone Response to Calcitriol Therapy in ESKD Patients. *J Am Soc Nephrol* 14: 2003.

- 246 Coco M, Feingold R, Faugere MC, Durkin P, Negolescu O, Wang G, MALLUCHE HH: Use of Pamidronate in ESRD Patients with Calcium Phosphate Product Prohibitive for Vitamin D Treatment. *J Am Soc Nephrol* 14: 2003.
- 247 Monier-Faugere MC, Mawad H, Trueba D, Friedler RF, MALLUCHE HH: Opposite Effects of Calcitriol and Paricalcitol on the PTH-(1-84)/C-Large Fragment Ratio in Patients on Hemodialysis. *J Am Soc Nephrol* 14, 2003.
- 248 MALLUCHE HH, Monier-Faugere MC, Wang G, Frazao JM, Charytan C, Coburn JW, Coyne D, Kaplan M, Baker N, McCary LC, Turner SA, Goodman WG. Cinacalcet HCl reduces bone turnover and fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT). ERA-EDTA 2004.
- 249 Koszewski NJ, Alimov AP, Park-Sarge OK, MALLUCHE HH: Potential Role for the Nuclear Factor Y (NF-Y) Transcription Factor Complex in Increasing PTH Gene Expression Associated with Renal Failure. *J Am Soc Nephrol* 2004.
- 250 MALLUCHE HH, Faugere, MC, Wang, G, Damment, SJP, Webster, I: No Evidence of Osteomalacia in Dialysis Patients Treated with Lanthanum Carbonate up to 5 years, *J Am Soc of Nephrol*, 2004.
- 251 MALLUCHE HH, Faugere, MC, Wang, G, Finn, WF: Lanthanum Carbonate and Bone: No Adverse Effects Observed after 1 Year of Treatment in a Randomized, Comparator-Controlled Trial, *J Am Soc of Nephrol*, 2004.
- 252 MALLUCHE HH, Wilson R, on Behalf of the SPD405-307 Lanthanum Study Group 2005 A 2-year randomized, comparator-controlled trial investigating the effect of lanthanum carbonate on bone. Poster presented at the 3rd World Congress of Nephrology, Singapore, 2005.
- 253 Alimov AP, Park-Sarge OK, Sarge KD, MALLUCHE HH, Koszewski NJ. VDR Heterodimer Binding to the Human PTH SP1/NF-Y_{DIST} DNA Element and Suppression of SP1/NF-Y Transactivation. *J Am Soc of Nephrol*, 2005.
- 254 Faugere, MC, Koszewski, NJ, Wang, G, MALLUCHE HH. PTH 7-84 Induces Increased iPTH Levels and Increased Number but Decreased Activity of Osteoblasts. *J Am Soc of Nephrol* 16: p 32A, 2005.
- 255 Koszewski, NJ, Alimov, AP, Park-Sarge, OK, MALLUCHE, HH. Suppression of Enhanced PTH Promoter Activity by Vitamin D and Its Analogs Requires an Intact Vitamin D Receptor (VDR) AF-2 Domain. *J Am Soc of Nephrol* 16: 64A, 2005.
- 256 Mawad, HW, Faugere, MC, MALLUCHE, HH. Effect of Phosphate Binders on Intact PTH, PTH 1-84, and the PTH/Large C Terminal PTH Peptide Ratio. *J Am Soc of Nephrol* 16: p280A, 2005.
- 257 Femhi, H, Osman Y, Nugyen K, Bhat S, Yee J, Faugere MC, MALLUCHE, HH. Assessment of Bone Turnover in African American Patients with CKD-5. *J Am Soc of Nephrol* 16: p493A, 2005.
- 258 Amerling R, Skiba M, Sahrkar S, Goretsky SS, Modugno M, Kuhlman M, Winchester J, MALLUCHE HH. Cinacalcet Lowers Calcium Phosphate Product (Ca X Phos) by Decreasing 1-84/7-84 PTH Ratio. *J Am Soc of Nephrol* 16: p887A, 2005.
- 259 de Villier WJS, Garvy B, Nagy TR, Safadi FF, MALLUCHE, HH, Faugere MC, Williams JP. Osteopetrosis in Oxidized LDL Receptor (SR-A) Knockout Mice. *J Bone Miner Res*, 2005.
- 260 MALLUCHE HH, Pratt RD. Evolution of renal osteodystrophy over 1 and 2 years during treatment with lanthanum carbonate or standard phosphate binders. *J Am Soc of Nephrol* 18: p57A, 2006.
- 261 Ferreira A, Frazao JM, Mueller R, Monier-Faugere MC, MALLUCHE HH. Effects of Sevelamer Hydrochloride and Calcium Carbonate on Bone Mineralisation and Turnover in Haemodialysis Patients: A One-Year Randomised, Open-Label Bone Biopsy Study Annual Meeting, European Renal Association, Glasgow, 2006.
- 262 Ferreira A, Frazao JM, Faugere MC, Mueller R, MALLUCHE HH. High prevalence of adynamic bone disease in haemodialysis patients despite adherence to K-DOQI guidelines. International Society of Nephrology-NeXus Symposium, Copenhagen, 2006.
- 263 Faugere MC, MALLUCHE HH. The rising prevalence of low bone turnover in renal osteodystrophy-is there a problem? *Int Soc Bone Morph* 2006.

- 264 Faugere MC, MALLUCHE HH: Adynamic Bone Disease – Is there a problem? Int Soc Bone Morph Philidelphia, 2006.
- 265 Porter D, Faugere MC, Wang G, Rosenblum W, Pienkowski D, MALLUCHE HH: Bone Turnover and Mineral Quality in Chronic Kidney Disease. Int Soc Bone Morph Philadelphia, 2006.
- 266 MALLUCHE HH, Pratt RD: Evolution of renal osteodystrophy over 1 and 2-years of treatment with lanthanum carbonate vs. standard phosphate binder therapy. J Am Soc of Nephrol 18: p 92A, 2006.
- 267 Adragao T, Ferreira A, Frazao JM, Galvao J, Baldaia J, Oliveira C, Ventura A, Rodrigues I, Sarmiento A, Santos C, de Carvalho B, Ribeiro S, Pereira O, Dickson J, Miranda V, Faugere MC, MALLUCHE HH. Vascular Calcifications and Bone Turnover in Hemodialysis Patients. Nephrol Dial Trans 21(suppl IV), 292, 2006.
- 268 Ferreira A, Frazao JM, Mueller R, Monier-Faugere MC, MALLUCHE HH. Effects of Sevelamer Hydrochloride and Calcium Carbonate on Bone Mineralisation and Turnover in Haemodialysis Patients: A One-Year Randomised, Open-Label Bone Biopsy Study, Nephrol Dial Trans 21(suppl IV): 293, 2006.
- 269 MALLUCHE HH, Faugere MC, Chami A, Herberth Z, Koszewski N: PTH Lost in the Woods? and Evolution of ROD in Patients on Maintenance Dialysis Treated with Std Phosphate Binder Therapy vs La Carbonate. 27th Annual Dialysis Conference Denver, CO, February 2007.
- 270 MALLUCHE HH, Pratt RD: Lanthanum Carbonate vs Standard Phosphate Binder Therapy: Evolution of Renal Osteodystrophy over 1 and 2 Years of Treatment. Poster Presentation, National Kidney Foundation, Annual Meeting, Orlando, FL, April 2007.
- 271 Adragao T, Ferreira A, Frazao JM, Gil C, Oliveira C, Galvao J, Sarmiento M, Ribeiro S, Dickson J, Carvalho B, Rodrigues I, Baldaia J, Pereira O, Faugere MC, MALLUCHE HH. Bone Mineral Density, Bone Histomorphometric Analysis and Vascular Calcifications in Hemodialysis Patients. Nephrol Dial Transplant, 22: (6) p.172, June 2007.
- 272 Gulay A, Mehmet O, Soner D, Huseyin T, Recep S, Meral K, Gulperi C, Sureyya S, Basci A, Monier-Faugere MC, MALLUCHE HH, Ok E. The Link Between Cardiovascular and Bone Disease in Hemodialysis Patients. Nephrol Dial Transplant, 22: (6) p.172p, June 2007.
- 273 Gulay A, Ercan O, Ebru G, Fatih K, Soner D, Mehmet O, Huseyin T, Savas S, Faugere MC, MALLUCHE HH. Predominance of Adynamic Bone Disease in Hemodialysis Patients. Nephrol Dial Transplant, 22: (6) p.172p, June 2007.
- 274 Porter DS, Monier-Faugere MC, Pienkowski D, MALLUCHE HH. Gender Related Differences in Bone Mineral Quality. J Bone Min Res 22, Suppl, S309, 2007.
- 275 MALLUCHE HH, Porter DS, Monier-Faugere MC, Pienkowski D. The Importance of Bone Quality in Patients with Renal Osteodystrophy. J Am Soc Neph 18: p303A, 2007.
- 276 Fahrleitner-Pammer A, Herberth J, Browning SR, Holzer H, MALLUCHE HH. Non-Invasive Markers of Bone Metabolism Predict Cardiovascular Morbidity and Mortality in Chronic Kidney Disease. J Am Soc Neph 18: p830A, 2007.
- 277 Chami A, Monier-Faugere MC, Lee JS, Wang G, Cantor T, MALLUCHE HH. Diagnosis of Bone Turnover by iPTH and PTH (1-84)/Large C-Terminal Fragments Ratio (PTH Ratio) in African American and Caucasian Patients with Chronic Kidney Disease Stage 5. J Am Soc Neph 18: p302A, 2007.
- 278 Herberth Z, Mawad H, Monier-Faugere MC, Herberth J, Cantor T, MALLUCHE HH. Comparison of 6 Commonly Used Parathyroid Hormone (PTH) Assays for Diagnosis of Bone Turnover in Hemodialysis Patients. J Am Soc Neph 18: p305A, 2007.
- 279 Muse K, Rudy T, MALLUCHE HH. Parathyroid hormone 1-84 (PTH 1-84) and its' Large C-Terminal Fragments Accross Pregnancy. Endocrine Society, San Francisco, 2008.
- 280 MALLUCHE HH, Lee J, Wang G, Herberth J, Monier-Faugere MC. Usefulness of the New TMV Classification of Renal Osteodystrophy. J Am Soc Nephrol 19: p.38A, 2008.

- 281 Adragao T, Herberth J, Monier-Faugere MC, Branscum A, MALLUCHE HH. Can Dual Energy X-ray Absorptiometry Predict Bone Mass in Patients on Chronic Hemodialysis? J Am Soc Nephrol 19: p.512A, 2008.
- 282 Asci G, Kircelli F, Sevinc E, Duman S, Ozkahya M, Toz H, Monier-Faugere MC, MALLUCHE HH, Ok E. Bone Markers for Non-Invasive Diagnosis of Adynamic Bone Disease in Hemodialysis Patients. J Am Soc Nephrol 19: p.4A, 2008.
- 283 Lomashvili K, MALLUCHE HH, Faugere MC, O'Neill C. Bisphosphonates Inhibit Vascular Calcification and Bone Formation in Uremic Rats. J Am Soc Nephrol 19: p.39A, 2008.
- 284 Pienkowski D, Porter D, Fauger MC, MALLUCHE HH. Difference in bone Mineral Quality between Caucasians and African Americans. ORS, 2008.
- 285 OK E, Asci G, Ceylan N, Duman S, Ozkahya M, Toz H, Faugere MC, MALLUCHE HH. Reduction of Calcium Exposure Slows Down Progression of Vascular Calcification and Improves Adynamic Bone Disease. Clin J Am Soc Neph Vol.3 No.6 LB-005, November 2008.